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i 
Abstract 
Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating disease 
resulting in chronic cough, shortness of breath, activity limitation and decreased pulmonary 
function.  Developments in imaging technology have provided sensitive and reliable modalities 
for evaluating regional lung function and disease progression, and there is a growing interest 
in the role of imaging the vasculature in COPD.  The ability to predict whether a patient is at 
risk of accelerated decline is important to disease management strategies.  We hypothesize that 
CT blood vessel volume measurements are significantly different in ex-smokers without 
COPD than in those with this disease and will be related to disease severity. 90 participants 
completed both baseline and follow-up visits: 41 ex-smokers without COPD (71±10yrs) and 
49 participants with COPD (71±8yrs). From baseline to follow-up, RA950 increased 
significantly for ex-smokers and GOLD II participants, while PV1 decreased significantly for 
GOLD I. There were no differences in VDP when grouped according to FEV1. Participants 
whose FEV1 increased by more than 20mL/year experienced a significantly smaller change in 
RA950 compared to those whose FEV1 decreased by more than 40mL. Independent samples t-
tests indicate a significant difference in the rate of PV1 progression between COPD groups 
with and without emphysema, but not VDP or RA950.  Emphysema, or COPD phenotype, is 
related to vascular structure within the lung and the progression of vascular remodelling. 
Future work should include investigations of sex-differences in airways disease, and the use of 
machine learning to predict disease progression with optimized CT imaging parameters. 
(247/250) 
Keywords 
Obstructive lung disease, chronic obstructive pulmonary disease, hyperpolarized gas lung 
imaging, 3He MRI, pulmonary vascular structure, remodeling, disease progression, computed 
tomography  
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Summary for Lay Audience 
Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating disease 
resulting in chronic cough, breathlessness, activity limitation and reduced lung function.  
Developments in imaging technology have permitted the evaluation and visualization of the 
complex effects of COPD within the lung.  The ability to predict how a patient’s disease will 
progress is important to managing it. Further, we do not fully understand how the disease 
develops, progresses, and how to predict who will get worse quickly. We can use MRI 
ventilation to image the lungs and see where air can or cannot go, which has allowed us to 
better understand their function. Similarly, measurements of small vessels that may be 
associated with inflammation, destruction, and disappear with damage, may help us better 
understand the disease process.  We hypothesize that measurements of small blood vessel 
volume are significantly different in participants without COPD than in those with this disease 
and related to disease severity. We evaluated 90 participants: 41 ex-smokers without COPD 
and 49 participants with COPD at baseline and 2.5 years later.  Ex-smokers and moderate 
COPD participants had more emphysema at follow-up, while participants with mild COPD 
had decreased small vessel volume and no change in emphysema. Both ex-smokers and 
participants with COPD had less ventilated lung at follow-up. Participants whose clinical 
measurements of lung function increased from baseline to follow-up experienced an increase 
in emphysema but significantly less change in small blood vessel volume compared to those 
whose lung function decreased the most in our sample. Participants with COPD who did not 
have emphysema experienced a decrease in small vessel volume. Vascular structure within the 
lung and how it changes with disease appears to be related to emphysema and disease severity. 
Measuring small vessel volume was more sensitive to changes in clinical lung function than 
lung ventilation.  This research demonstrates that using multiple modalities to evaluate lung 
disease over time can help researchers and clinicians to better predict a patient’s outcome and 
provide more specific and timely treatment.  
 (329/350) 
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CHAPTER 1 
1 INTRODUCTION 
The lung is a complex organ that allows for the distribution and exchange of gases in and 
out of the bloodstream for all tissues in the body. In this chapter we will establish the basis 
for COPD research (1.1), discuss the basic structures within the lung and their function 
(1.2) followed by an investigation of the consequences of COPD on these structures and 
overall lung function in section 1.3. Section 1.4 will briefly discuss the significance of 
disease progression in COPD. In section 1.5, clinical measurements of lung function are 
discussed, followed by imaging technologies and their applications in the study of COPD 
(1.6). This chapter serves to establish the background and basis for the following chapters. 
Finally, the hypothesis and objectives of this thesis are described in section 1.7. 
 Motivation and Rationale 
Prevalence and Burden 
Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating disease 
resulting in chronic cough, shortness of breath, activity limitation and decreased pulmonary 
function for those affected. Approximately 2 million Canadians over the age of 35 are 
currently diagnosed with COPD,1 and will be a continued burden on the healthcare system2 
due to an aging population with a smoking history and environmental pollution.1 The major 
risk factor for developing COPD is tobacco smoke, as approximately 25% of smokers will 
develop COPD in their lifetime,3 with a lifetime risk of diagnosis of approximately the 
same by the age of 80.4 This lung disease is predominantly considered to be smoking-
related, and often affects people who are current or ex-smokers. However, it is possible to 
also develop COPD based on a genetic mutation5 or after exposure to environmental or 
occupational hazards where inhaled particulates can cause lung damage.6 Women and men 
are affected in relatively equal proportions.1  
  
 
2 
Patients experience frequent exacerbation leading to hospitalization with COPD being the 
leading cause of hospitalization in Canada,7 as is illustrated in Figure 1.1. Further, 
comorbidities such as bronchiectasis increase the morbidity and mortality of COPD.8 It is 
challenging to predict which patients will be at risk of disease exacerbation, which can 
contribute to extended hospital stays, increased morbidity, and increased risk of further 
exacerbation or death. Disease exacerbation is the most costly to the healthcare system at 
$10,000 per patient per hospital stay, adding up to an annual cost of over $600 million in 
Canada.9 Current diagnostic techniques probe the whole lung and large airways, yet they 
are insensitive to the regional heterogeneity of disease presentation and progression 
observed within and between patients;10 developments to imaging technology have 
provided sensitive and reliable modalities for evaluating regional lung function, as well as 
evaluating disease progression.11  
COPD has historically been considered to have two distinct phenotypes.12 As our 
understanding of this disease has developed, we now know that there are multiple disease 
phenotypes based on the cause of the disease.1,13,14 Despite this evidence, treatment in the 
clinical setting is largely focused on symptom management as opposed to disease 
modifying therapies with a targeted and patient specific approach to the prevention of 
exacerbation.6 Accordingly further study of the etiology, progression, and treatment of this 
disease is crucial in providing targeted, patient centred and specifically effective treatment. 
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Figure 1.1: Canadian hospitalizations due to COPD.  
This figure demonstrates that cases of COPD represent the greatest number of 
hospitalizations in Canada, more than angina, asthma and heart failure. COPD patients also 
have more repeated hospitalizations than in other causes. Figure Adapted from Canadian 
Institute for Health Information, Health Indicators Report 2008.2 
Gaps in Clinical Measurements 
Given the alarming and progressive disease morbidity and burden, there is a specific need 
to better identify patients at risk of disease development or progression. One way to inform 
this gap in our understanding of COPD progression is to investigate the role of vascular 
changes relative to clinical measurements. We understand that COPD is a heterogeneous 
disease and current clinical diagnostic measurements do not always reflect this variability 
in symptoms and disease presentation or progression. There is an urgent need to further 
our understanding of this disease in order to characterize disease phenotypes and ultimately 
improve treatment and management strategies. 
 Structure and Function of the Lung 
The purpose of the respiratory system is to facilitate gas exchange by providing oxygen for 
the blood to circulate to tissues within the body and the removal of gaseous waste products, 
such as carbon monoxide (CO2), ultimately maintaining the body’s tightly regulated 
homeostasis. The structure of the lung consists of the airways, parenchyma and vasculature. 
An organized network of these structures is optimized to allow for efficient and effective 
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function. In a healthy lung, this process is highly optimized and during daily activities or 
resting, humans do not use this organ to its fullest capacity.15 This however, this changes 
drastically in the context of diseases such as COPD, wherein damage to the parenchyma 
and airways can result in remodeling and inflammation of these structures with catastrophic 
and permanent effects on the lung’s ability to properly serve its function. In this section, 
we will discuss the basic structures of the lung and a discussion of how these structures are 
affected in the context of disease will follow in the next (1.3).  
1.2.1 Airways 
The adult human lung comprises an extensive and highly organized network of airways. 
The large airways consisting of generations 0 (trachea) to 7. More proximal airways are 
encompassed by cartilaginous rings which allow them to stay open during the process of 
ventilation. The airway walls are comprised of a smooth muscle layer, allowing them to 
dilate or constrict, and which may become inflamed in COPD, restricting airflow.16 The 
innermost layer is the airway epithelium which contains cilia that move mucous and dirt 
out of the airways.15 The clearance of mucous is an important process in the prevention 
and removal of airway obstructions which would prevent downstream ventilation and 
regional loss of function. The main airway bifurcates to each lung, and then each lobe, and 
finally to each segment. Each segmental bronchus then bifurcates to form sub-segmental 
bronchi, sub-sub-segmental bronchi, and so on to ventilate 19 distinct bronchopulmonary 
segments.15 As is outlined in Figure 1.2, the first 16 generations are conducting airways 
and no gas exchange occurs in this region; conversely, the last 7 are considered to be the 
respiratory zone of the lung, where gas exchange occurs.15 The smallest airways, terminal 
airways, end in alveoli, the site of gas exchange in the lung.  
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Figure 1.2: Idealized human airway generation diagram. 
Adapted from Respiratory Physiology: The Essentials 10th edition.15  
1.2.2 Parenchyma 
In the healthy lung, the parenchyma is made up of approximately 500 million alveoli,15 
which fill with air upon inspiration. At the individual level, each alveolus is a small sac 
with a wall thickness of one cell, surrounded by a network of capillaries. When filled with 
air, the laws of partial pressures govern the exchange of gasses across this thin membrane; 
both oxygen (O2) and carbon dioxide (CO2) diffuse down their concentration gradients into 
and out of the bloodstream, respectively.15 
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1.2.3 Vessels 
The pulmonary circulation is comprised of two distinct circuits: bronchial and pulmonary. 
The bronchial circulation makes up a relatively small volume of the total pulmonary 
vasculature, approximately 1%,17 and is responsible for supplying oxygen to the bronchial 
tree and removing waste products as part of the systemic circulation. This circuit stems 
from the descending aorta, following the posterior aspect of the bronchial tree. The arteries 
form a plexus within the muscular layer of the bronchial wall and extending down to the 
terminal bronchioles. The bronchial venules drain to veins, as illustrated in Figure 1.5, 
which then either flow into the pulmonary circulation via anastomoses.17  
The pulmonary circulation is that with which we are the most familiar and is fundamentally 
important as it permits gas exchanged at the alveolus to enter the bloodstream and travel to 
all tissues in the body. The pulmonary circulation leaves the right ventricle through the 
pulmonary artery, carrying deoxygenated blood to the lungs for gas exchange to occur. A 
network of capillaries surrounds each individual alveolus, and following gas exchange, 
oxygenated blood returns to the left atrium via the pulmonary veins, and leaves the left 
ventricle via the aorta to circulate through the rest of the systemic circulation.15 
Within each capillary are a stream of red blood cells containing the protein hemoglobin 
(Hb) or carbaminohemoglobin (HbCO2). Carbon dioxide is passively unloaded at the 
capillaries following its concentration gradient and diffusing into the alveolus to be 
exhaled. Similarly, oxygen diffuses down its concentration gradient into the bloodstream 
and binds to Hb forming oxyhemoglobin (HbO2).
15 This process is illustrated in Figure 
1.3. 
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Figure 1.3: Diagram of gas exchange from the alveolus into the pulmonary capillary. 
This figure illustrates oxygen (blue) entering the alveolus, diffusing across the alveolar 
capillary membrane into the bloodstream to bind with hemoglobin on red blood cells. 
Carbon dioxide (green) diffuses from the bloodstream to the alveolus and is removed upon 
exhalation. Based on Respiratory Physiology: The Essentials 10th edition.15 
O2=oxygen, CO2=carbon dioxide, HbCO2=carbaminohemoglobin, Hb=hemoglobin, 
HbO2=oxyhemoglobin. 
The pulmonary vessels are important in the context of disease. Muscular arteries consist of 
a smooth muscle layer which, similar to airways, is able to contract and relax in order to 
decrease or increase the vascular lumen area. This smooth muscle layer allows for the 
tightly controlled regulation of blood pressure within the pulmonary circuit. Further, 
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receptors embedded in the vascular endothelium are sensitive to changes in blood gas 
concentration and inflammatory signaling molecules from neighbouring or distant tissues. 
18 The pulmonary vasculature is an extremely important component in support of proper 
lung function, and as will be discussed in subsequent sections, is susceptible to changes in 
the disease state.  
 Pathophysiology of Chronic Obstructive Pulmonary 
Disease 
Despite the lungs being over-engineered to facilitate gas exchange, damage can occur to 
the tissues due to smoking or environmental exposures to toxins that reduce the lung’s 
abilities to properly perform this task. In COPD, this exposure leads to airway remodeling 
and tissue destruction that increases as the disease progresses.  
 
Figure 1.4: Lung parenchyma and airways in healthy lungs and in obstructive lung 
disease. 
The top images in this figure illustrate the airway lumen and wall in a normal healthy lung, 
as compared to a lung with obstructive lung disease. The airway wall is inflamed, and the 
lumen is narrowed. The bottom row illustrates the lung parenchyma in healthy cases with 
many alveoli, as compared to emphysema, which occurs in obstructive lung disease where 
alveolar walls are destroyed.  
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1.3.1 Emphysema 
In many cases, destruction of alveolar air sacs results in a loss of density within the lung 
parenchyma termed emphysema. As Illustrated in Figure 1.4, this loss of surface area 
within the lung results in enlarged airspaces, loss of terminal bronchioles, and ultimately a 
reduced capacity of the lung to exchange gases consistent with the extent of 
emphysematous lung volume.12,19  
Three distinct types of emphysema exist, overlap of pathologies in clinical diagnoses with 
unique aetiologies. Centrilobular is associated with chronic cigarette smoking and is 
present in the central regions close to the bronchi with normal distal tissue. Panlobular 
emphysema is present in the lower portions of the lungs and distributed evenly from 
proximal to distal regions of the lungs; this type of emphysema is most common in alpha-
1 antitrypsin deficiency, a genetic mutation that results in the development of emphysema 
in patients irrespective of smoking history. Finally, paraseptal emphysema is also related 
to smoking, but can be caused by fibrosis and lung infection as well, and presents as distal 
or peripheral tissue destruction.5,20,21 Clinical cases often include multiple pathological 
presentations of emphysema.20 
1.3.2 Chronic Bronchitis 
Inflammation and obstruction within the airway results in an inflammatory response of the 
airway smooth muscle, as illustrated in Figure 1.4. Chronic bronchitis is the clinical term 
used to describe symptoms of excessive mucous production, generally as a result of chronic 
inflammation. Excess mucous can cause airway obstruction and a cough, as well as an 
inability to ventilate regions of the lung, causing reduced function.12 
1.3.3 Pulmonary Vascular Remodeling  
Late stage COPD can in some cases impair cardiovascular function.22 Patients with COPD 
experience a drop in blood oxygen saturation (SaO2) as their disease progresses and their 
lungs lose the ability to exchange gases efficiently.12  In response to low levels of blood 
oxygen (hypoxia), the pulmonary vasculature constricts in order to optimize 
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ventilation/perfusion efficiency. In cases of chronic hypoxic vasoconstriction, a subsequent 
increase in pulmonary arterial pressure becomes pathological. In pulmonary arterial 
hypertension (PAH), wherein pathological changes within the lung place additional stress 
on the cardiovascular system, the right ventricular wall is thickened and cardiac function 
impaired.23,24 Oxygen therapy is ultimately used in COPD in order to overcome the chronic 
hypoxemia experienced by patients and to decrease pulmonary arterial pressure.24,25 
 
Figure 1.5: Pulmonary and bronchial vascular structure within the lung. 
This figure illustrates the anatomy of vascular and pulmonary veins and arteries within a 
single bronchopulmonary segment. Adapted from “Structure and Function of the 
Respiratory System,” Pediatric Critical Care 4th edition. Elsevier 2011.26 Permission to 
reproduce is included in Appendix B. 
The end stage of PAH is termed cor pulmonale, and is the result of chronic pulmonary 
arterial hypertension caused by chronic lung disease.24 This occurs in approximately 50% 
of patients; however, the prevalence is challenging to accurately determine.25 The 
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consideration of this condition is therefore important to our understanding of the complex 
interplay between the pulmonary and cardiovascular systems.  
While the relationship between vascular remodeling and COPD has been long 
established,27-29 there has been a growing interest in the role of imaging the vasculature in 
COPD,30,31 and the literature contains a number of more recent studies evaluating small 
vessel volume in various populations.32-35 Recent studies have demonstrated that vascular 
pruning occurs in COPD resulting in a loss of small vessels and decreased vessel density, 
which has been validated using histology.36 Cigarette smoke has been identified as a 
mediator of these changes, and can directly result in vascular remodeling,33,35 which is 
consistent with previous work related to the effects of smoking.29 It has also been 
hypothesized that airway damage observed in bronchiectasis is driven by remodeling of 
the pulmonary vasculature.37 A recent study reported that remodeling of the pulmonary 
vasculature does progress in direct correlation with emphysema over a two-year follow-up 
period.38 Other groups have utilized similar methodology in order to investigate vascular 
remodeling in lung disease.39-41 
Histological studies have also been conducted, and have reported bronchial arterial wall 
hypertrophy;30 remodeling of the pulmonary vasculature such as wall thickening, lumen 
narrowing and pruning in COPD have all been published.22,30 These changes are believed 
to be attributed to increased inflammatory cytokine signaling within the lung as well as a 
paradoxically upregulated growth factor signaling.42 
The detrimental effects of smoking on the lung vasculature have been well characterized. 
Tobacco smoke can directly affect the vasculature by promoting vascular remodeling.31 
Further, as the alveolar walls are destroyed as in the case of emphysema, destruction of 
capillary and small arterioles within these tissues are removed as well.35,36  
Within the clinical setting, cardiovascular comorbidities represent a large proportion of 
hospitalizations in patients with COPD and contribute to increased morbidity and 
mortality.1,22 While this direct relationship is not the focus of this work, it is an important 
example of the complex relationships between the vascular and pulmonary systems in the 
disease state. Developing a better understanding of the complex relationships between the 
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cardiovascular and respiratory systems in the context of COPD serves an unmet clinical 
need and provides an opportunity for the application of imaging technologies to determine 
intermediate disease endpoints.  
 Disease Progression 
Disease progression in COPD can be affected by a number of factors. Firstly, age-related 
decline in lung function is a normal physiological process, wherein peak lung function is 
achieved around the age of 25, and declines steadily with age.43,44 Figure 1.6 illustrates the 
effect that tobacco smoking has on this decline, although not all smokers experience the 
same negative effects, as some are more susceptible to cigarette smoke than others. Disease 
exacerbation is another factor that can affect the rate of lung function decline, as well as 
patient quality of life in COPD.9,11,38,45 The ability to predict whether a patient is at risk of 
exacerbation or accelerated decline is important to treatment and management strategies. 
While difficult to predict, this is currently measured using pulmonary function testing and 
self-assessments of symptoms and quality of life, as discussed in section 1.5. 
 Clinical Measures of Global Lung Function 
1.5.1 Pulmonary Function Testing 
Spirometry 
The diagnosis of COPD is based predominantly on pulmonary function testing results. 
Airflow obstruction can be measured using spirometry. A handheld spirometer is illustrated 
in figure 1.7. Pulmonary function testing results can be reported as absolute values in units 
of volume, or as a percent predicted (%pred). These predicted values are based on a 
population mean according to the patients’ race, sex, age and height.46 In considering the 
forced expiratory volume in one second (FEV1), this describes the percentage of total lung 
volume that a person can blow out in the first second of expiration. When divided by the 
forced vital capacity (FVC), the total amount of air that a person can forcibly expire, the 
FEV1/FVC ratio provides a measure of airflow obstruction.
15  
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Figure 1.6: Natural history of COPD through the lifespan. 
This diagram demonstrates the trajectory of normal age-related decline of lung function in 
never-smokers (yellow) from its peak at age 25. By contrast, in regular current smokers 
susceptible to the detrimental effects of tobacco smoke, this decline is accelerated (red) 
towards disability and death. In ever smokers who quit, this decline can be slowed towards 
the trajectory of normal decline (green and purple), illustrating the lung’s ability to partially 
recover. Adapted from Fletcher & Peto 1977.43 
Lung function peaks around the age of 25, and normal lung function decline occurs with 
age. As is illustrated in Figure 1.6, smoking can increase age-related lung function decline. 
An abnormal ratio of FEV1/FVC less than 0.70 is indicative of airflow limitation 
characteristic of COPD.6 Table 1-1 outlines the pulmonary function testing criteria for the 
diagnosis and grading of COPD as per the GOLD criteria.6 Another important component 
of diagnosing COPD is the investigation of parenchymal tissue integrity, or the presence 
of emphysema. This can be done by measuring the diffusing capacity of the lung to carbon 
monoxide (DLCO),
15 the current gold-standard for the assessment of emphysema; this can 
also be accomplished by imaging the lung using computed tomography6 as discussed 
below, and these measurements have been shown to have good agreement.47 
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Figure 1.7: Clinical plethysmography box and handheld spirometer. 
Plethysmography box for measuring lung volumes (left) and handheld spirometer. 
Diffusing capacity is evaluated using a mixture of gases of a known concentration. This 
typically consists of a small amount of carbon monoxide (CO) (1-2%), an inert tracer gas 
such as neon (Ne), and balanced with nitrogen (N2) and oxygen (O2).
6,48 The patient inhales 
the gas mixture, holds their breath for a short amount of time, compared to the amount 
inhaled, compared to a predicted value and reported as a percentage of that (%pred). A 
high diffusing capacity is expected in a healthy person, whereas reduced DLCO in COPD 
indicative of the presence of emphysema. 
Pulmonary function testing is also used to classify the severity of a patient’s disease 
according to the Global Initiative for Chronic Lung Disease guidelines, on a scale of 1-46, 
as outlined in Table 1.1.  
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Table 1.1: Pulmonary function testing diagnostic cut-offs from the Global Initiative 
for Chronic Lung Disease (GOLD). 
 FEV1/FVC FEV1 
GOLD Grade I <0.70 >80% 
GOLD Grade II <0.70 >50%pred, <80%pred 
GOLD Grade III <.070 >30%pred, <50%pred 
GOLD Grade IV <0.70 <30%pred 
These criteria do not differentiate the relative causes of obstruction, airway inflammation 
or emphysema, and do not provide information regarding the heterogeneity of the disease 
throughout the lungs. Additionally, while this process is standardized for reproducible 
results,49 assuring good results in children or patients with difficulty following instructions 
or performing testing to completion may have inaccurate results. In the next section, we 
will discuss imaging technologies used in order to overcome these limitations.  
Plethysmography 
Whole body plethysmography may be used to measure lung volumes by applying Boyle’s 
law, which describes the relationships between pressure and volume in a closed system at 
a constant temperature.50 In a box of known volume, as illustrated in Figure 1.7. when a 
participant applies pressure by inhaling or exhaling the volume change can be measured 
and reported.50 Figure 1.8 illustrates commonly reported lung volumes.  
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Figure 1.8: Representative schematic of lung volumes during tidal breathing and 
forced expiration. 
This figure illustrates a time-volume graph during a patient’s tidal breathing, followed by 
an inhalation, full expiration, and return to tidal breathing.  
FRC=functional residual capacity, FEV1=forced expiratory volume in 1 second, 
FVC=forced vital capacity, RV=residual volume, TLC=total lung capacity. 
An increase in residual volume occurs in patients with COPD due to parenchymal tissue 
remodeling, which reduces the lung’s elastic properties and make it challenging to expel 
gas upon exhalation. Further, airway inflammation and obstruction impair the movement 
of air in but also out of the lungs. Both of these cases result in gas trapping and might lead 
to characteristic hyperinflation of lung volumes in COPD. This can be observed by 
increases in both the patient’s residual volume (RV) and total lung capacity (TLC), and 
functional residual capacity (FRC). An increased FRC means that the patient’s tidal 
breathing occurs at volumes closer to TLC than what is observed in a healthy person. 
1.5.2 Symptom Reporting 
The investigation of COPD impact on quality of life can also be achieved using 
questionnaires with the aim of establishing the disease burden on the patient. The St. 
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George’s Respiratory Questionnaire is an established tool used in the evaluation of 
COPD.51 Questions evaluate the effects of obstructive lung disease on the patients’ daily 
activities including the symptoms that they experience day to day, exacerbations and 
control of symptoms, as well as activity limitations. The report provides a symptom score, 
activity score, impact score and total score. A low score is indicative of low burden. A 
change of 4 points for the total score is the minimum clinically significant indication of a 
change in symptoms.52 A limitation of using self-report measures to evaluate chronic 
disease is the bias introduced by variables that may affect symptom reporting such as the 
patients’ sex.53 Further, patients with chronic disease may have unconsciously modified 
their activities in order to manage their disease over time, and may not identify specifically 
that, for example, they do not take the stairs due to exercise limitations related to their 
COPD. 
It is possible to evaluate a patient’s activity limitation by evaluating a patients’ rating of 
perceived exertion (RPE) and dyspnea using the Borg Scale.54 The RPE scale ranges from 
6-20 and uses brief descriptions of each level from 6 “no effort” to 20 “maximum effort”. 
The Borg dyspnea scale is similar, ranging from 0 to 10.55 This scale is commonly used to 
evaluate exertion during exercise testing, which is discussed in the following section. 
1.5.3 Exercise Testing & Activity Limitation  
A more objective method of investigating activity limitation in COPD is the use of exercise 
testing. The six-minute walk test (6MWT) is a simple measure of sub-maximal exercise 
capacity. The outcome measure is the distance walked by a patient over 6 minutes, doing 
laps of a 100 foot (30 meters) straight hallway at their own pace. A clinically important 
change in this measurement is 70 m in COPD.56 Sub-maximal exercise testing is well 
tolerated in in this group, and while other methods of testing exist, the 6MWT was among 
the most strongly correlated to FEV1.
57 A limitation of exercise testing to evaluate disease 
burden is that some patients have physical limitations unrelated to their COPD, for 
example, a knee or hip replacement, which may reduce their ability to perform the test 
regardless of disease severity.  
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Lifestyle changes are recommended as part of managing COPD in the clinical setting, 
primarily quitting smoking. As is illustrated in Figure 1.6, research has demonstrated that 
some of the damage incurred from chronic tobacco smoking can be reversed and quitting 
can alter the course of lung decline in smokers.43 Further, cardio-pulmonary rehabilitation 
has been shown to improve symptoms in COPD, as well as overall patient quality of life. 
Maintaining or improving a patient’s exercise capacity is an important factor for overall 
health, as inactivity puts the patient at risk for a number of comorbidities.1   
1.5.4 Limitations of pulmonary function testing and the role of imaging 
While the assessments of lung function, symptom reporting, and exercise capacity 
discussed above are well understood within the clinical setting, they are limited by the fact 
that they provide general information only. By contrast, imaging measurements provide 
regional information about the lung’s structure and function, which can be assessed both 
qualitatively and quantitatively. In section 1.6, we will explore various imaging 
technologies applied in lung imaging, including structural methods (1.6.1) such as x-ray, 
computed tomography, and proton magnetic resonance imaging (MRI). Additionally, we 
will explore quantitative analysis techniques (1.6.2) applied in COPD, including 
hyperpolarized gas MRI, ultra-short echo time and Fourier decomposition MRI. Imaging 
technologies better characterize the heterogeneity of disease presentation within a single 
patient and have been established as sensitive and reliable measurement tools which 
correlate with global assessments. These technologies have benefits and downsides and 
will be discussed in detail below. The application of imaging technologies in the study of 
COPD is imperative to the overarching goal of this thesis. 
 Imaging Pulmonary Structure and Function 
1.6.1 Structural and Anatomical Imaging 
Planar X-ray 
The most commonly available imaging modality for chest imaging is planar x-ray, or 
projectional radiography. This imaging techniques functions by sending x-rays from a 
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source, through the sample and the x-ray attenuation is measured by a detector. The 
resulting imaging is a two-dimensional reconstruction of the sample, as demonstrated in 
Figure 1.9. Benefits of this technique is that it provides a good image resolution, and is 
abundantly available in the clinical setting.58 
 
Figure 1.9: Chest x-ray in a patient with COPD showing lung hyperinflation as a 
result of emphysema. 
A flattened diaphragm is a common sign of lung hyperinflation in COPD. Case courtesy 
of A. Prof Frank Gaillard, Radiopaedia.org, rID: 8512. CC BY-NC-SA 3.0 License 
(Creative Commons) information is included in Appendix B 
Computed Tomography 
Computed tomography (CT) has been used to image the chest and lungs since the late 
1970’s.59,60 Based on known linear attenuation coefficients, researchers soon determined 
that emphysematous regions of the lung could be easily visualized using chest CT,61 and 
that the presence of emphysema correlated with pulmonary function measurements.19,61  
High resolution CT (HRCT) is the current gold-standard of lung imaging for the clinical 
setting. It provides high resolution structural information, giving precise and detailed 
insight into structures such as the airways, vessels, and parenchymal tissue integrity. 
Attenuation coefficients are measured based on density, wherein -1000 Hounsfield units 
(HU) indicates the presence of air and 0 HU establishes the presence of water. The 
attenuation of emphysematous or low density lung tissue is therefore close to that of air, 
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and the most commonly reported threshold is -950 HU,62 although -910 is sometimes 
used.63 A chest CT in an ex-smoker, as well as participants with COPD are shown in Figure 
1.10. A major benefit to using CT imaging is that the spatial resolution is exceptionally 
high compared to other imaging modalities. A limitation of using CT is of course the 
radiation dose associated with imaging. The low-dose, high resolution CT protocol used in 
our lab gives a dose of 1.8 mSv to the patient. Micro-CT images have been acquired in 
order to measure the airways and vasculature; however, this method is only indicated in 
ex-vivo or animal studies.  
The ability to quantify and measure structures and volumes of the lungs has become an 
important tool for the diagnosis and monitoring of lung disease. Quantitative CT analysis 
has been used to investigate changes in parenchyma, airway and vessels count, number and 
density in COPD33,37,64 leading to increased application of this method in the clinical 
setting.65 Analysis of airways count and measurements,64 low attenuating area, low 
attenuating clusters,38 blood vessel density and volume,34,36 peripheral vessel volume and 
cross-sectional area33,35 have all been reported in COPD from clinical CT, and are 
illustrated in Figure 1.10. Measurements such as airway wall thickness (WT, mm) and 
lumen area (LA, mm2) can be measured from the cross-section of an airway in a CT image. 
Normal lung tissue has an attenuation threshold of approximately -700 HU. 
Emphysematous lung volume is calculated by dividing the volume of lung attenuating 
below -950 HU by the total lung volume (RA-950). Gas trapping may also be measured 
using CT, as trapped tissue is less dense, but is denser than emphysematous lung regions. 
The most broadly accepted threshold is of -856 HU.66 
Blood vessel volume can be calculated using a combination of density threshold method 
followed by a circularity filter and line-tracing algorithm to assure continuity.67 More 
recent methods have taken advantage of machine learning methods.39,68,69 Studies have 
reported increased volumes of emphysematous tissues within the lungs of patients with 
COPD, and these levels correlate with the severity of the patient’s disease.20 Studies 
investigating changes in the airways of patients with COPD have identified that the airway 
walls of COPD patients are thicker than those of healthy controls,70 and when counted, 
have reduced numbers in relation to the patient’s disease severity.64 Analysis techniques 
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for vascular structure have been used to evaluate the relationship between CT emphysema, 
pulmonary arterial pressure,31 and small vessel cross-sectional area (CSA5%).
38 The authors 
determined that vascular pruning, or a loss of small vessels within the lung, is related to 
the extent of emphysema within the lung and also related to increased pulmonary arterial 
pressure, indicative of vascular disease.31 
 
Figure 1.10: 3He MRI and computed tomography images and 3D models of vascular 
structure and airways in an ex-smoker without COPD as well as participants COPD. 
Left panel: chest CT in an ex-smoker without COPD, as well as representative participants 
with GOLD I, II and III/IV COPD. Middle panel: 3D rendering of vascular trees. Right 
panel: 3D rendering of airway trees demonstrating a decrease in the number of airways 
with increasing disease severity. 
Ex-smoker: 80-year-old male, VDP=4%, RA950=1%, TBV=151mL; GOLD I: 67-year-old 
male, VDP=8% RA950=2%, TBV=115mL; GOLD II: 60-year-old female, VDP=16% 
RA950=27%, TBV=106mL; GOLD IV: 68-year-old female, VDP=34%, RA950=33%, 
TBV=162mL. 
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GOLD=global initiative for obstructive lung disease, 3D=three dimensional, 
CT=computed tomography, VDP=ventilation defect percent, RA950=relative area of the 
lung with attenuation below -950 HU, TBV=total blood volume. 
While the consequences of disease on these organs are relatively well characterized, only 
recently have researchers begun to explore how imaging can be used to detect pulmonary 
vascular remodeling as a biomarker for disease stage or progression. Advances in both high 
resolution and functional image acquisition techniques as well as advanced image analysis 
methodologies have provided the opportunity to quantitatively evaluate vascular structures 
within the lungs, and how it relates to lung function, something that was previously next to 
impossible to accomplish.71  These techniques will be discussed further in section 1.5.1.  
Parametric response mapping has emerged as a technique that applies multiple methods of 
quantitative CT analysis in order to elucidate multiple COPD phenotypes. By acquiring 
inspiration-expiration CT scans and generating voxel-wise maps of emphysema, gas 
trapping, and functional small airways disease, researchers were able to identify relative 
volumes of each in participants with COPD.72,73 Parametric response mapping has been 
utilized in order to elucidate multiple imaging phenotypes of COPD.  
Proton Magnetic Resonance Imaging 
It is possible to image the lungs using magnetic resonance imaging (MRI), however due to 
extensive air-tissue interfaces, it is challenging to acquire images with adequate signal, and 
tissue destruction due to disease leaves even less tissue to image. This is due to a rapid loss 
of signal following the radio frequency (RF) pulse. A benefit of using MRI is that this 
method does not deliver any radiation dose to the patient, and therefore is ideal for 
longitudinal studies. Beyond the technical limitations with this technique, access and cost 
are also barriers to its widespread application in the clinical setting.  
Ultra-short Echo Time  
Ultrashort echo time (UTE) MR imaging can be used to acquire very high-resolution 
images that provide better resolution than conventional proton MR techniques. This is 
accomplished by using a very small flip-angle and a short echo time (TE). A short TE 
means that there is very short relaxation time that overcomes the rapid signal decay due to 
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air-tissue interfaces within the lungs.74 This method provides images with signal intensity 
values which are directly related to tissue density.75 
1.6.2 Functional Imaging 
Hyperpolarized Gas Magnetic Resonance Imaging  
In order to overcome the limitations of proton MRI, hyperpolarized noble gas MR imaging 
may be used to measure ventilation within the lungs. Gasses, such as helium-3 (3He) and 
xenon-129 (129Xe) are stable isotopes that can be hyperpolarized in order to increase their 
MR signal.74,76 Hyperpolarized gas images are acquired during a single breath-hold and are 
well tolerated by patients.77-80 Gas images are superimposed onto proton images at the same 
lung volume for anatomical reference.81 This was first accomplished in 1994 using 129Xe, 
a safe general anesthetic, in the mouse lungs,82 and shortly thereafter in humans;83 however, 
the field quickly switched to 3He imaging. While 3He has a greater gyromagnetic ratio and 
provides greater signal in imaging, 129Xe is less expensive and a far more abundant 
resource,74 and therefore the field has transitioned back to 129Xe imaging.84 
Dynamic wash-in and wash-out methods have been used in both healthy and diseased 
lungs. The theory behind this technique is that regions that might appear as ventilation 
defects on a single breath-hold MR image are regions with slower time constants for filling 
than in a single breath-hold due to tissue properties or airflow obstructions,85 and therefore 
the ventilation of partially obstructed regions may be investigated. This can be 
accomplished using hyperpolarized gas such as 3He or 129Xe, or fluorinated gas.86,87 This 
technique is accomplished by administering a known amount of hyperpolarized gas over 
time using either the wash-in or wash-out methods, and reporting ventilation defect percent 
as well as wash-in/out time.85,88 This method is less clinically applicable due to the 
extended imaging time and doses of gas required,88 however, could provide valuable 
information regarding tissue properties and gas trapping.89 
Single breath-hold MRI of the lung has been extensively used in the study of COPD.90,91 
There is strong agreement between CT measurements of emphysema, pulmonary function 
testing and MRI ventilation defect percent (VDP),11,92 wherein participants with decreased 
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pulmonary function testing measured using spirometry have increased VDP.11 MRI has 
been used by our group to evaluate disease progression in COPD, and these measurements 
are importantly related to, and sensitive to changes in, participants’ self-reported quality of 
life.11,92 Upon imaging, bright areas are regions that are filled with gas, whereas dark areas 
are termed ventilation defects as can be visualized in Figure 1.10. This can be expressed 
as a percent of the total lung area that is not ventilated, known as the VDP. The minimal 
clinically important difference in VDP using 3He MRI is of 2% or 110mL.93 This is 
important for evaluating a change in disease severity in patients in longitudinal studies or 
for evaluating a treatment response.  
Despite the shortcomings of conventional proton MR imaging for generating tissue signal 
within the lung, hyperpolarized gas MRI can be used to assess tissue integrity using the 
apparent diffusion coefficient (ADC). Measured in units of cm2/s, ADC provides a measure 
of the distance a gas particle travels within the lung in a certain period of time. In healthy 
lung tissues, alveoli and alveolar septa divide the parenchymal space into extremely small 
compartments that limit the movement of any individual gas particle. When alveolar walls 
and septa are destroyed, as is in the case of emphysema, the gas particles are free to travel 
further distances within the lung in a similar amount of time, producing a high ADC 
value.78,94 This technique is exciting due its application as an indirect spatial measurement 
of emphysema within the lung without exposure to ionizing radiation.95 A limitation of the 
ADC technique is that it is impossible to evaluate tissue integrity for regions of the lung 
that are not ventilated, as no gas is able to travel there and no coefficient can be generated. 
Xenon Dissolved-phase MRI 
Xenon gas, unlike helium and fluorine, is uniquely able to diffuse into the blood stream. 
Single breath-hold 129Xe imaging therefore allows for measurements of both regional lung 
ventilation as well as gas exchange; when this gas diffuses into the bloodstream it is 
associated with a chemical shift that can be differentiated from the gas phase Xe within the 
lungs.89 This method provides a measurement not only of how well the lungs are ventilated 
upon inhalation, but also of how well ventilated regions are able to exchange gases at the 
alveolar-capillary level. 
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Fourier Decomposition MRI 
Fourier decomposition (FD) MRI is a technique that provides a voxel-wise map of 
ventilation and perfusion within the lung. A frequency signal for blood flow according to 
the cardiac rhythm, as well as for the respiratory rate is generated within in each voxel. In 
collecting a time series of images of the lungs, ventilation and perfusion maps can be 
generated based on mean signal intensity over a period of minutes.96 This method has 
recently been compared to 19F washout MRI in patients with COPD. The authors 
demonstrated that FD-MRI correlated strongly with pulmonary function testing 
measurements as well as washout results.97 This method has also been compared to 3He 
MR imaging with good agreement.98 
Summary 
Overall, imaging technologies provide important structural and functional information that 
allows a deeper understanding of the heterogeneity of lung disease within a single patient. 
Various structural and functional modalities exist, each with benefits and downsides. When 
combined with clinical measures of lung function, we can gain insight which is clinically 
understood and grounded in the clinical setting, while improving the information available 
to physicians and researchers, allowing the identification of novel endpoints and 
biomarkers in COPD. 
 Thesis Objectives and Hypotheses 
COPD is a chronic, debilitating and irreversible disease, with a significant economic 
burden, and for which disease exacerbation is related to increased morbidity and mortality.6 
Although the role of vascular remodeling,17,22-24,31 angiogenesis18,30,42 and pruning in 
COPD32,35,36 have been explored, recent work has demonstrated the potential for CT 
vascular structure as a biomarker of disease severity and progression.38 The relationship of 
CT vascular measurements with and lung ventilation has, to our knowledge, yet to be 
elucidated. 
  
 
26 
The overarching objective of this thesis is to explore the role of vascular structure and how 
it relates to established measures of lung structure and function in a unique dataset. 
Specifically, we aim to:  
1) To compare CT blood vessel volume measurements in ex-smokers without 
COPD and those with mild, moderate, and severe disease,  
 
2) To evaluate relationships between imaging and clinical biomarkers of chronic 
obstructive pulmonary disease, and 
 
3)  To investigate disease progression in COPD using multimodality imaging.  
 
We hypothesize that CT blood vessel volume measurements are significantly different in 
ex-smokers without COPD than in those with this disease, and that CT blood vessel 
measurements are strongly and significantly related to MRI ventilation in ex-smokers. This 
work will conclude with a discussion both the impact and limitations of this work and will 
explore potential future directions.  
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CHAPTER 2 
2 CT PULMONARY VESSELS AND MRI VENTILATION 
IN CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE: RELATIONSHIP WITH WORSENING FEV1 
IN THE TINCan COHORT STUDY 
 
In the previous chapter we explored the structural and functional consequences of COPD, 
as well as various methods of measurement. The state of the literature was established, and 
this provided a basis for the application of multimodality imaging to elucidate the role of 
imaging the pulmonary vasculature in obstructive lung disease. In this chapter, the main 
thesis objectives and hypotheses are addressed. The purpose of this study is to evaluate the 
relationship between CT pulmonary vasculature with MRI lung ventilation, and to 
investigate how these relationships change over time.  
This work was accepted to for publication Academic Radiology on March 5th, 2020. 
 Introduction 
The 2020 statement of the Global Initiative for Chronic Lung Disease (GOLD)1 reported 
that in 2010, the number of cases of Chronic Obstructive Pulmonary Disease (COPD) in 
persons aged 40 and over was at least 385 million and the global prevalence of COPD was 
12%, both of which are predicted to increase in the next two decades. Global estimates of 
three million deaths/year are predicted to dramatically increase in the next 20 years because 
tobacco cigarette smoking rates are rising in the developing world and demographic aging 
is also climbing in the developed world.2 The measurement of COPD airway, parenchyma 
and vascular phenotypes in patients to optimize care remains challenging3,4 and because of 
this, GOLD staging criteria and the confirmatory diagnosis of COPD still rely on 
pulmonary function tests1 based on expiratory flow measurements made at the mouth. 
Unfortunately, the onset of, and progression of COPD are believed to initiate in the 
terminal airways,5,6 which are impossible to measure using pulmonary function tests. 
Moreover, cardiovascular comorbidities that cannot be measured or estimated using 
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pulmonary function tests are responsible for a large share of COPD hospitalizations and 
for increased COPD morbidity and mortality.7,8   
Pulmonary imaging measurements of COPD promise improved disease phenotyping and 
better risk predictions for COPD exacerbations and accelerated disease progression.  In this 
regard, thoracic x-ray computed tomography (CT) serves as the gold-standard COPD 
imaging approach and has been extensively used in COPD cohort studies including Genetic 
epidemiology of COPD Study (COPDGene),9 Subpopulations and Intermediate Markers 
in COPD Study (SPIROMICS),10 Multi-Ethics Study of Atherosclerosis (MESA),11 
Canadian Cohort of Obstructive Lung Disease Study (CanCOLD)12 and Evaluation of 
COPD to Longitudinally Identify Predictive Surrogate Endpoints (ECLIPSE).13 
Hyperpolarized noble gas MRI has also been developed to sensitively measure ventilation 
heterogeneity14 and airspace enlargement in COPD patients,15 both of which are related to 
COPD severity,16 exercise limitation17 and symptoms.18  
A recent longitudinal study of COPD demonstrated that the forced expiratory volume in 
one second (FEV1) changed very little in patients in whom there was substantial vascular 
pruning and airway remodeling.19 Pulmonary vessels with a cross-sectional diameter < 
5mm were also shown to be related to emphysema and pulmonary hypertension20 and other 
work demonstrated the relationship between cigarette smoking and small vessel volume,21 
as well as a relationship between pulmonary vascular tree pruning and COPD 
progression.22,23 More recently, histological examinations confirmed pulmonary vascular 
trimming and airway wall remodeling in COPD patients.24 Taken together, these findings 
support the notion that CT small vessel measurements may serve as an intermediate 
endpoint of COPD. To our knowledge, no study has investigated the relationships between 
CT pulmonary vasculature structure and MRI ventilation (airway function).   
In the Thoracic Imaging Network of Canada (TINCan) study,25 volume-matched CT and 
MRI was acquired in 176 ex-smokers; spatial correlations between MRI ventilation defects 
and conventional CT measurements of emphysema and airways disease were reported.  
This unique dataset provides an opportunity to investigate CT pulmonary vascular tree 
measurements and MRI ventilation over time in a relatively large group of ever-smokers.  
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We hypothesized that CT pulmonary vascular tree measurements would be significantly 
related to MRI ventilation and CT emphysema measurements in ex-smokers and that their 
change over time would be related to changes in emphysema.  Hence, the objective of this 
study was to evaluate the relationship between CT pulmonary vasculature with MRI lung 
ventilation in ex-smokers and to investigate how these measurements change over a 
relatively short period of time.   
Materials and Methods 
2.1.1 Study Design and Participants 
Participants provided written informed consent to an ethics-board approved (Institutional 
Ethics Board #00000984) and registered (NCT02279329 clinicaltrials.gov) protocol and 
underwent thoracic CT, MRI and pulmonary function tests as previously described.25 
Inclusion criteria included a history of cigarette smoking > 10 pack years, age between 50 
and 85 years at baseline and exclusion criteria consisted of claustrophobia and any 
contraindications for MRI or CT. Ex-smokers had ceased smoking ≥1-year prior to the 
study visit but there was no maximum cut-off for when ex-smokers had ceased smoking. 
COPD was defined as post-bronchodilator forced expiratory volume in 1 second 
(FEV1)/forced vital capacity (FVC) ratio less than 0.70 according to the modified GOLD 
criteria.1 This study was prospectively planned and performed from December 2010 to 
January 2019; participants underwent a single two-hour visit and performed spirometry, 
plethysmography, quality-of-life questionnaires, exercise capacity tests, MRI and CT as 
previously described.25 Long-term follow-up was prospectively planned for 24 ±6 months  
and 120±12 months after the baseline visit.25 All evaluations were performed 20 minutes 
after administering Novo-Salbutamol HFA using a metered-dose inhaler (four doses of 100 
ug, Teva Novopharm Ltd., Toronto, ON, Canada) through a spacer (AeroChamber Plus 
spacer, Trudell Medical International, London, ON, Canada).  All the data generated during 
the study are available from the corresponding author. 
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Figure 2.1: Consort diagram for TINCan Cohort Study and participants evaluated. 
hundred and sixty-six consented to participation and 172 participants completed the 
baseline visit (Visit 1) while 90 participants completed the follow-up visit (Visit 2) and 
were included in analysis. 
 
2.1.2 Pulmonary Function and Quality of Life Tests 
Spirometry, plethysmography, and measurement of the diffusing-capacity-of-the-lung for 
carbon-monoxide (DLCO) were performed according to American Thoracic 
Society/European Respiratory Society guidelines26-28 using a body plethysmograph 
(MedGraphics Elite Series, MGC Diagnostic Corporation, St. Paul, MN, USA) with an 
attached gas analyzer. The St. George’s Respiratory Questionnaire was administered,29 and 
a six-minute-walk-test  to measure the six-minute walk-distance (6MWD) was also 
performed.30 
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2.1.3 MRI 
Anatomical proton (1H), hyperpolarized 3He static ventilation, and diffusion weighted MRI 
were performed on a 3.0 T Discovery MR750 system (GE Healthcare, Milwaukee, WI, 
USA) with broadband imaging capabilities as previously described. 1H MRI was acquired 
using a whole-body radio-frequency coil during a breath hold after inhalation of 1.0 L of 
N2 as previously described.
25 1H and 3He images were acquired using a fast gradient 
recalled echo pulse sequence with the following parameters respectively: (TR/TE/flip 
angle=4.7ms, 1.2ms, 30°) and (TR/TE/flip angle=4.3ms, 1.4ms 7°).25,31 3He polarization 
was performed as previously described25 and all 3He MRI was performed using a single-
channel rigid elliptical transmit-receive chest coil (RAPID Biomedical, Wuerzburg, 
Germany) as previously described.  
2.1.4 CT 
Within 30 minutes of the MRI, CT was acquired on a 64-slice Lightspeed VCT scanner 
(GE Healthcare, Milwaukee, WI, USA) under breath-hold after inhalation of 1.0 L N2 from 
functional residual capacity.25  CT images were acquired with the following parameters: 
beam collimation of 64 x 0.625mm, 120kVp, effective mAs of 100, 500ms tube rotation 
time, pitch of 1.25, and image reconstruction with a standard convolution kernel to 
1.25mm.25 Total effective dose was estimated as 1.8 mSv using the ImPACT CT patient 
dosimetry calculator (based on Health Protection Agency [UK] NRBP-SR250). 
2.1.5 Image Analysis 
3He MRI ventilation defect percent (VDP) was semi-automatically segmented using in-
house custom-built software using MATLAB (R2018a, Natick, MA, USA) as previously 
described.31 Diffusion-weighted images were automatically processed to generate apparent 
diffusion coefficients (ADC).17 CT image analysis was completed using VIDA Vision 
Software (VIDA Diagnostics Inc., Coralville, IA, USA) for measurements of the relative 
area of the lung with attenuation <-950 HU, and for pulmonary vascular measurements 
based on segmented vascular trees as previously described.32 Briefly, for pulmonary vessel 
segmentation, the approach was based on tube enhancement using a cylindrical shape 
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model that employed an eigenvalue of the Hessian matrix which served as a filter to extract 
vessels. At junctions, vessel branch points were identified from noise by applying a 
thinning method which then allowed for the selection of objects with many branch points. 
Pulmonary vascular total blood volume (TBV) was calculated for the entire segmented 
vascular tree and a 1 voxel filter was used to generate and the percent of pulmonary vessels 
with a radius < one pixel (PV1), similar to previously described results using VIDA Apollo 
software.33 
 
Figure 2.2: Baseline MR and CT images for representative ex-smoker without COPD 
and representative participant III COPD. 
Left panel provides coronal centre-slice 3He MRI ventilation in cyan co-registered with 1H 
anatomical image; Middle panel provides coronal CT reconstruction of same slice with 
relative area of the lung with voxels < -950 Hounsfield units (RA950) shown in yellow; 
Right panel provides 3D reconstruction of CT pulmonary vessels at baseline in purple.  
Ex-smoker without COPD is an 83-year-old male, FEV1 %pred=104%, VDP=4 =%, RA950= 
1%, TBV=150 mL, PV1=45% 
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GOLD I COPD participant is an 88-year-old male, FEV1 %pred=88%, VDP=10%, 
RA950=4%, TBV=100 mL, PV1=54% 
GOLD III COPD participant is a 68-year-old female, FEV1 %pred=37%, VDP=34%, RA950= 
33%, TBV=160 mL, PV1=60%  
MRI=magnetic resonance imaging; CT=computed tomography; GOLD=global initiative 
for chronic obstructive lung disease; FEV1=forced expiratory volume in 1 second; 
VDP=ventilation defect percent; RA950=relative area of the lung with CT attenuation < -
950 HU. 
2.1.6 Statistical Methods  
Statistical analyses were completed using SPSS (ver. 25; IBM Statistics, Armonk, NY, 
USA). Longitudinal analyses were evaluated using repeated measures ANOVA as well as 
independent t-tests to determine relationships between baseline and follow-up 
measurements.  Paired sample t-tests were used to determine subgroup (All participants, 
Ex-smokers, all COPD and GOLD I, II, III/IV) differences between time points for specific 
variables. The annual rate of change in FEV1 was determined for all participants and they 
were stratified into three subgroups based on change in FEV1/year as follows: 1) a decrease 
of greater than 40mL/year (n=40), 2) a change in FEV1 between a 20mL/year increase and 
a 40mL/year decrease (n=25), and 3) an increase of greater than 20mL/year (n=25). 
Relationships were evaluated using linear regression in GraphPad Prism (Prism v8; La 
Jolla, CA, USA). All results were considered statistically significant when the probability 
of making a Type I error was less than 5%. 
 Results 
As shown in the consort diagram provided in Figure 2.1, 266 participants enrolled in the 
study and 172 participants completed all imaging examinations at baseline.  Of those 
participants who did not complete Visit 1, most simply did not attend after enrollment and 
consent (n=43) or did not complete MRI (because of coil fit, n=10 or claustrophobia, n=3) 
or CT (radiation dose concerns, n=5). After 31±7 months (range=8-50 months), 90 
participants returned for a complete follow-up visit. There were 29 ex-smokers and 50 
COPD participants lost to follow-up who could no longer be reached by telephone or email. 
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Table 2.1: Participant demographics at baseline for all ex-smokers with and without 
COPD and at baseline for those who returned for follow-up.  
 
BMI=body mass index, SaO2=digital oxygen saturation, 6MWD=six minute walk distance, 
%pred=percent predicted, FEV1=forced expiratory volume in 1 second, FVC=forced vital 
capacity, RV=residual volume, TLC=total lung capacity, DLCO=diffusing capacity of the 
lung for carbon monoxide. A one-way ANOVA was used to test for differences between 
participants that attended both baseline and follow-up visits (n=90) and those that attended 
the baseline visit (n=172).  
 
As shown in Table 2.1, of the 90 participants who completed both the baseline and follow-
up visit, 41 were ex-smokers without spirometric evidence of COPD (71±10yrs) and 49 
participants were ex-smokers with COPD (71±8yrs). Table 2.1 also shows that the 
participants who completed both baseline and follow-up visits reported significantly 
greater (more normal) FEV1, (p=0.02), RV (p=0.01) and RV/TLC (p=0.004) at baseline 
than all participants completing the baseline visit.   
Figure 2.2 shows MRI and CT findings for representative participants at baseline including 
an ex-smoker without COPD and participants with GOLD grade I and grade III COPD.  
With increasing disease severity there were a qualitatively more and larger ventilation 
defects and a greater relative area of emphysema as shown in the yellow RA950 mask. 
 All Participants Participants with Follow-up  
Parameter 
(±SD) 
All 
n=172 
Without 
COPD 
n=71 
With 
COPD 
n=101 
All 
n=90 
Without 
COPD 
n=41 
With 
COPD 
n=49 
p-
value 
Females n (%) 67 (39) 31 (44) 36 (36) 36 (42) 18 (44) 16 (33) - 
Age y 71 (10) 70 (10) 71 (10) 71 (9) 71 (10) 71 (8) .642 
BMI kg/m2 27 (5) 29 (4) 26 (4) 28 (4) 30 (4) 26 (4) .158 
SaO2 % 96 (3) 96 (4)  95 (3) 96 (3) 95 (5)  96 (2) .808 
6MWD m 386 (94) 403 (96) 373 (92) 404 (85) 398 (100) 408 (71) .087 
FEV1 %pred 76 (29) 98 (19) 60 (24) 83 (27) 102 (18) 68 (23) .021 
FVC %pred 90 (18) 92 (17) 88 (20) 94 (17) 94 (17) 95 (18) .054 
FEV1/FVC 62 (19) 81 (7) 49 (13) 65 (17) 81 (6) 52 (11) .097 
RV %pred 139 (49) 107 (22) 162 (50) 127 (41) 106 (20) 145 (45) .011 
TLC %pred 111 (18) 101 (13) 118 (18) 109 (15) 102 (12) 114 (16) .164 
RV/TLC %pred 123 (28) 106 (17) 135 (29) 115 (25) 103 (15) 125 (28) .004 
DLCO %pred 64 (23) 78 (21) 54 (20) 68 (21) 77 (17) 60 (20) .129 
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Figure 2.2 shows there were no visually obvious differences in CT total blood volume or 
PV1 with increasing disease severity.  
Table 2.2:  Demographics for participants who attended both baseline and follow-up  
 
BL=baseline, FU=Follow-up, BMI=body mass index, SaO2=oxygen saturation, 
6MWD=six minute walk distance, %pred=percent predicted, FEV1=forced expiratory 
volume in 1 second, FVC=forced vital capacity, RV=residual volume, TLC=total lung 
capacity, DLCO=diffusing capacity of the lung to carbon monoxide. Paired t-tests were used 
to test for within-group changes at follow-up.  
  
As shown in Table 2.3 (supplement), the ex-smoker subgroup reported significantly 
different RA950 (p<0.0001), VDP (p<0.0001), TBV (p<0.0001) and PV1 (p=0.01) at 
baseline as compared to all COPD subgroups. There were significant differences between 
GOLD I and GOLD II subgroups for RA950, VDP and PV1, and between GOLD I and 
GOLD III/IV for all imaging measurements. VDP was also significantly different between 
GOLD III/IV and GOLD II subgroups at baseline. Table 2.4 (supplement) also shows that 
at baseline, VDP was significantly different for the 23 participants with CT emphysema 
(RA950  6.8%,34) as compared to the subgroup of COPD participants without emphysema 
(n=26). The subgroup of participants with CT emphysema also reported significantly 
different baseline VDP, TBV and PV1 as compared to all ex-smokers. 
 Ex-smoker GOLD I GOLD II GOLD III/IV 
Parameter (±SD) 
BL 
n=41 
FU 
n=41 
p- 
value 
BL 
n=15 
FU 
n=15 
p- 
value 
BL 
n=23 
FU 
n=23 
p- 
value 
BL 
n=11 
FU 
n=11 
p- 
value 
Female n (%) 18 (44) 18 (44) - 1 (7) 1 (7) - 11 (48) 11 (48) - 4 (36) 4 (36) - 
Age y  71 (10) 73 (10) .0001 75 (8) 78 (8) .0001 68 (7) 72 (7) .0001 70 (9) 72 (9) .0001 
BMI kg/m2 30 (4) 30 (4) .721 28 (4) 28 (4) .766 26 (4) 25 (3) .632 26 (6) 26 (5) .923 
SaO2 % 95 (5) 96 (2) .791 96 (1) 95 (3) .183 96 (2) 94 (3) .002 95 (2) 94 (3) .427 
6MWD m 417 (83) 404 (76) .074 434 (39) 408 (59) .041 423 (71) 407 (80) .152 362 (84) 336 (97) .216 
FEV1 %pred 102 (18) 103 (21) .465 97 (12) 99 (12) .387 62 (8) 59 (14) .164 40 (5) 39 (10) .634 
FVC %pred 94 (17) 96 (19) .112 111 (13) 110 (14) .527 94 (13) 90 (12) .099 75 (10) 67 (15) .093 
FEV1/FVC 81 (6) 79 (7) .027 64 (4) 64 (5) .942 50 (9) 50 (10) .310 41 (7) 44 (10) .171 
RV %pred 105 (20) 103 (20) .336 116 (27) 119 (19) .685 140 (25) 143 (32) .505 202 (46) 193 (45) .437 
TLC %pred 101 (11) 96 (12) .0001 111 (11) 110 (10) .744 113 (14) 111 (17) .601 124 (22) 121 (17) .510 
RV/TLC %pred 103 (15) 106 (16) .338 104 (18) 107 (15) .343 123 (17) 127 (16) .388 160 (17) 157 (21) .737 
DLCO %pred 79 (16) 86 (17) .0001 76 (20) 78 (23) .483 60 (16) 61 (20) .463 45 (14) 45 (14) .971 
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Table 2.2 shows baseline and follow-up pulmonary function, lung volume, 6MWD and 
DLCO measurements for all 90 participants who completed the follow-up visit including 
ex-smokers without COPD (n=41 at baseline and follow-up), GOLD I, (n=16 at baseline 
and n=15 at follow-up), GOLD II, (n=23 at baseline and n=21 at follow-up) and GOLD 
III+IV (n=11 at baseline and n=14 at follow-up) COPD. Paired t-tests revealed significant 
differences for each subgroup at follow-up; unpaired test results are shown in Table 2.5 
(online supplement) because the subgroup sample sizes changed over time with some 
participants reported worsening pulmonary function at the follow-up visit.  In the ex-
smoker subgroup, there were significant but small changes in FEV1/FVC, TLC and DLCO, 
whilst in the GOLD I subgroup there was a significant decline in the 6MWD.  
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Figure 2.3: Baseline and follow-up CT and MR imaging for representative 
participants with COPD. 
Top panels provide coronal centre-slice 3He MRI ventilation in cyan co-registered with 1H 
anatomical image; Bottom panels provide coronal CT reconstruction of same slice with 
relative area of the lung < -950 Hounsfield units (RA950), shown in yellow. 
GOLD II participant is a 76-year-old male, follow-up time=38 months, FEV1%pred=56% 
(BL) and 38% (FU); VDP=24% (BL) and 33% (FU); RA950=11% (BL) and 19% (FU)  
GOLD III participant is a 74-year-old male, follow-up time=28 months, FEV1%pred=34% 
(BL) and 30% (FU); VDP=34% (BL) and 45% (FU); RA950=18% (BL) and 22% (FU).  
MRI=magnetic resonance imaging; CT=computed tomography; GOLD=global initiative 
for chronic obstructive lung disease; FEV1=forced expiratory volume in 1 second; 
%pred=percent predicted; VDP= ventilation defect percent; RA950=relative area of the lung 
with CT attenuation < -950 HU.  
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Figure 2.3 shows MRI ventilation and CT RA950 masks and measurements for two 
representative COPD participants at baseline and follow-up. For both participants, there 
was qualitatively worse MRI ventilation (shown in cyan in top panel), and emphysema 
(shown using the RA950 mask in yellow in bottom panel) at the follow-up visit.  
 
Figure 2.4: Imaging measurements at baseline and follow-up. 
Paired t-tests were used to determine significance of within-group changes over time for:  
RA950: ES=1±1% (BL) and 3±4% (FU), p<.02; C=9±9% (BL) and 11±12% (FU), p=.02; 
GOLD I=4±3% (BL) and 5±7% (FU) , p=.17; GOLD II=10±10% (BL) and 13±13% (FU) 
, p=.03; GOLD III/IV=15±11% (BL) and 17±10% (FU) , p=.70. 
 
VDP: ES=7±4% (BL) and 9±6% (FU), p=.002; C=16±10% (BL) and 19±11% (FU), 
p=.005; GOLD I=8±4% (BL) and 11±3% (FU), p=.001; GOLD II=17±9% (BL) and 
18±10% (FU), p=.42; GOLD III/IV=29±5% (BL) and 33±9% (FU), p=.04. 
 
TBV: ES=114±24mL (BL) and 115±36mL (FU), p=.46; C=146±30mL (BL) and 
142±35mL (FU), p=.005; GOLD I=134±29 (BL) and 142±29mL (FU), p=.06; GOLD 
II=145±27 (BL) and 132±34mL (FU), p=.03; GOLD III/IV=167±25 (BL) and 162±36mL 
(FU), p=.81. 
 
PV1: ES=49±4% (BL) and 49±5% (FU), p=.72; C=52±6% (BL) and 51±6% (FU), p=.02;  
GOLD I=51±5% (BL) and 48±4% (FU), p=.002; GOLD II=52±6% (BL) and 52±6% (FU), 
p=.40; GOLD III/IV=53±6% (BL) and 52±6% (FU), p=.69. 
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BL=baseline; FU=follow-up; RA950=relative area of the lung with attenuation < -950 HU; 
VDP=ventilation defect percent; TBV=total blood vessel volume; PV1=relative volume of 
pulmonary vessels with radius < 1 voxel; ES=ex-smokers without COPD; C=all 
participants with COPD; GOLD=global initiative for chronic obstructive lung disease; 
*p<.05, **p<.01 
 
Quantitative results are shown in Figure 2.4 for baseline and follow-up RA950, VDP, CT 
pulmonary vascular total blood volume (TBV) and percent of pulmonary vessels with 
radius < one voxel (PV1) measurements.  For RA950 shown in the top left panel, there were 
significant changes at follow-up for ex-smokers (p=0.02), all COPD (p=0.002) and GOLD 
II COPD (p=0.03) subgroups. For VDP shown in the top right panel, there were significant 
changes at follow-up for ex-smokers (p=0.002), all COPD (p=0.005), GOLD I (p=.001) 
and GOLD III/IV (p=0.04) subgroups. For TBV shown in the bottom left panel, there were 
significant changes at follow-up for all COPD (p=0.005) and GOLD II subgroups (p=0.03) 
whereas there was a trend for a change at follow-up reported by GOLD I participants 
(p=0.06). Finally, there were significant changes at follow-up for PV1 in the all COPD 
(p=0.02) and GOLD I COPD (p=0.002) subgroups.  
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Figure 2.5: Change in imaging measurements at follow-up for participants stratified 
by mean annual change in FEV1. 
Top panel shows histograms for the FEV1 rate of change for all participants (n=90, mean=-
40±93mL/year), ES (n=41, mean=-42±107mL/year), C (n=49, mean=-39±80mL/year), GI 
(n=15, mean=22±93mL/year), GII (n=23, mean=-45±75mL/year) and GIII/IV (n=11, 
mean=-49±75mL/year). Participants who reported a decrease at follow-up in FEV1 < -
40mL/year (n=40), between -40 and +20mL/year (n=25) and >+20mL/year (n=25) are 
shown in white, grey and black ±SD, respectively for ΔRA950 ΔVDP ΔTBV and ΔPV1. T-
tests were used to evaluate subgroup differences as shown above. 
ΔRA950 for ΔFEV1>+20= -0.24±0.66 %/year, ≥-40, ≤+20= 0.50±1.6%/year, <-40= 
1.2±2.1%/year,  
Significant differences for >+20 and ≥-40mL to ≤+20, p=.44; ≥-40mL to ≤+20 and <-40, 
p=.18; >+20 and < -40, p=.01. 
ΔVDP for ΔFEV1>+20=1.4±3.2%/year, ≥-40, ≤+20= 1.1±2.4%/year, <-40=1.5±2.9%/year 
Significant differences for subgroups: >+20 and ≥-40mL to ≤+20, p=.77; ≥-40mL to ≤+20 
and <-40, p=.63; >+20 and < -40, p=.89. 
ΔTBV for ΔFEV1>+20=0.70±8.6mL/year, ≥-40, ≤+20= -2.7±9.2mL/year, <-40=-
2.0±8.3mL/year 
  
 
49 
Significant differences for subgroups:  >+20 and ≥-40mL to ≤+20, p=.19; ≥-40mL to ≤+20 
and <-40, p=.75; >+20 and < -40, p=.21. 
ΔPV1 for ΔFEV1: >+20= -.26±1.6%/year, ≥-40, ≤+20= -1.2±2.0%/year, <-40= 
.10±1.4%/year  
Significant differences for subgroups >+20 and ≥-40mL to ≤+20, p=.07; ≥-40mL to ≤+20 
and <-40, p=.007; >+20 and < -40, p=.33. 
ALL=all participants; ES=ex-smokers; C=all participants with COPD; GOLD=global 
initiative for chronic obstructive lung disease; FEV1=forced expiratory volume in 1 second; 
PV1=relative volume of pulmonary vessels with radius <1 voxel; RA950=relative area of 
the lung with CT attenuation <-950 HU; VDP=ventilation defect percent; TBV=total blood 
vessel volume. *p<.05, **p<.01. 
 
As shown in the frequency distributions provided in the top panel of Figure 2.5, the mean 
annual change in FEV1 was -40±93mL/year for all participants, -42±107 mL/year for ES, 
-22±93mL/year for GOLD I, -45±75mL/year for GOLD II and -49±75mL/year for GOLD 
III/IV participants. A one-way ANOVA revealed no significant difference in the mean 
annual FEV1 rate of change for the subgroups (p=0.87).  We acknowledge that the mean 
annual change in FEV1 measured here is greater than previous reports and with greater 
heterogeneity 9,35,36.  
The bottom panels in Figure 2.5 show the annual rate of change for RA950, VDP, TBV and 
PV1  for three subgroups stratified by the mean change in FEV1/year (from right to left): a 
decrease of greater than 40mL/year (n=40), a change in FEV1 between a 20mL/year 
increase and a 40mL/year decrease (n=25), and an increase of greater than 20mL/year 
(n=25) in white, grey and black bars respectively. The annual rate of RA950 change for 
participants with FEV1 decrease of greater than 40mL/year was also significantly different 
compared to the subgroup with a 20mL/year FEV1 increase (p=0.01). The annual rate of 
change for PV1 for the subgroup with an FEV1 decrease of greater than 40mL/year was 
also significantly different compared to the subgroup with a change in FEV1 between a 
20mL/year increase and a 40mL/year decrease (p=0.007). Finally, as shown in Table 2.4, 
the very small difference in mean annual change in PV1 between ex-smokers without 
COPD and COPD participants with CT emphysema was significant (p=0.013), whilst no 
other imaging measurement annual changes were significantly between COPD subgroups 
with and without emphysema. 
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Figure 2.6: Relationships for PV1 and pulmonary function test measurements. 
PV1 linear regression with FEV1 y=-.047x+54.423, r=-.25, p=.02; 
PV1 linear regression with FEV1/FVC: y =-.107x+57.483, r=.-35, p=.001; 
PV1 linear regression with log10(RA950): y =4.000x+48.870, r=.44, p=.0001; 
PV1 linear regression with DLCO: y=-.048x+53.743, r=-.19, p=.08; 
PV1 linear regression with VDP: y=.078x+49.632, r=.14, p=.20; 
∆PV1 linear regression with ∆RA950: y=.214x-1.126, r=.26, p=.02. 
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As shown in Figure 2.6, we also explored relationships for PV1 with pulmonary function 
measurements. Baseline values of PV1 weakly correlated with baseline values of FEV1 %pred 
(r=-.25; p=0.02), FEV1/FVC (r=-.35; p=0.001) and log RA950 (r=.44; p=0.0001), but not 
DLCO (r=-.19; p=0.08) or VDP (r=.14; p=0.20). Figure 2.6 also shows that the mean 
change in PV1 was also weakly but significantly related to the change in RA950 (r=.26; 
p=0.02) and the annual rates of change were also significantly but weakly related (r=.28, 
p=0.01) (data not shown). 
 
Figure 2.7: 3D model of 3He MRI ventilation and CT vessels for four representative 
participants. 
Ventilation (cyan) and vessels (purple) for representative participants who did and did not 
report the mean absolute change in FEV1 at the follow-up visit:  
Top panels show GOLD II COPD at follow-up with > mean absolute change in FEV1: 
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67-year-old female, follow-up time=33 months, FEV1%pred=53% (BL) and 50% (FU); 
Absolute change in FEV1= -110mL; VDP=12% (BL) and 10% (FU); TBV=110mL (BL) 
and 110mL (FU); PV1=56% (BL) and 60% (FU); RA950=6% (BL) and 8% (FU). 
75-year-old male, follow-up time=33 months, FEV1%pred=108% (BL) and 79% (FU); 
Absolute change in FEV1= -1170mL; VDP=17 (BL) and 26 (FU); TBV=182 (BL) and 
153mL (FU); PV1=54% (BL) and 52% (FU); RA950=3% (BL) and 2% (FU). 
 
Bottom panels show GOLD II COPD at follow-up with < mean absolute change in FEV1: 
71-year-old female, follow-up time=49 months, FEV1%pred=58% (BL) and 59% (FU); 
Absolute change in FEV1= -60mL; VDP=11% (BL) and 12% (FU); TBV=120mL (BL) 
and 120mL (FU); PV1=54% (BL) and 60% (FU); RA950=12% (BL) and 17% (FU) 
57-year-old male, follow-up time=34 months, FEV1%pred=62% (BL) and 62% (FU); 
Absolute change in FEV1= 0mL; VDP=8 (BL) and 9% (FU); TBV=128 (BL) and 130mL 
(FU); PV1=49% (BL) and 50% (FU); RA950=1% (BL) and 2% (FU). 
 
Figure 2.7 shows 3He MRI ventilation co-registered with CT vessel trees at follow-up for 
four representative participants including two COPD participants at follow-up with a 
change in FEV1 greater than the mean for all participants and two COPD at follow-up with 
FEV1 change less than the mean for all participants.  In the top two panels, regions of 
mismatched vascular structure and ventilation are shown in the top panels for two 
participants with follow-up time of` 33 months. For a 67-year-old female shown in the top 
left panel, the absolute change at follow-up in FEV1 was -110mL, whilst the change for 
RA950 and VDP was 2% and PV1 increased 4%. For a 75-year-old male, shown in the right 
panel, the absolute change in FEV1 was a decrease of 1170mL, VDP worsened from 17% 
to 26%, TBV decreased from 182mL to 153mL, PV1 increased from 52% to 54% and RA950 
decreased 1% at follow-up. 
In the bottom panels, regions of mismatched vessel tree and MRI ventilation are shown for 
two participants at follow-up with GOLD grade II COPD. For the 71-year-old female 
shown in the bottom left panel, the follow-up time was 49 months and there was an absolute 
change in FEV1 of -60mL, whilst the change for RA950 and PV1 were 5% and 6% 
respectively with negligible changes in VDP and TBV. For a 57-year-old male in the 
bottom right panel, there was no change in FEV1%pred over 34 months and there were 
negligible changes in all other imaging measurements, although there appears to be 
substantial MRI ventilation-vessel tree mismatch in the anterior region of the lung. 
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 Discussion 
We measured pulmonary CT vessel measurements and MRI ventilation at baseline and 
31±7 months later in 90 ex-smokers including 41 without COPD and 49 with COPD and 
observed: 1) participants who returned for follow-up reported significantly more normal 
FEV1, RV and RV/TLC at baseline than all participants who completed the baseline visit, 
2) significant differences in baseline RA950, VDP, TBV and PV1 between ex-smokers and 
COPD participants as well as VDP (but not TBV or PV1) in COPD participants with and 
without emphysema, 3) while the annual rate of change in FEV1 (-40±93mL/year) was not 
different among participant subgroups, the annual rate of change for RA950 and PV1 was 
significantly different in participants with an accelerated annual rate of FEV1 decline as 
compared to participants with a diminished annual rate of FEV1 decline, and, 4)  significant 
but weak relationships for PV1 with FEV1, FEV1/FVC and RA950 and for the mean annual 
change in PV1 with the mean annual change in RA950. 
First, we observed that participants who returned for follow-up had significantly more 
normal pulmonary function and lung volumes at baseline than all participants completing 
the baseline visit. This suggests that measurements reported here may provide conservative 
estimates of longitudinal change because they stem from participants who were in better 
health on their first visit so they were perhaps more likely to attend the follow-up visit.  
The follow-up period was also similar to ECLIPSE (3 years) 35 and CanCOLD (2.5 years)36 
but the TINCan cohort was a convenience and not a population sample. 
Second, at baseline, and as expected, we observed significant differences in RA950, VDP, 
TBV and PV1 between ex-smokers and COPD participants.  Differences between ex-
smokers and participants with COPD for emphysema,19,37 small vessel volume20,38 and 
ventilation17 have been previously observed. To our knowledge however this is the first 
report of ventilation and CT pulmonary vascularity at baseline and again 2.5 years later. In 
addition, we observed that VDP measurements were significantly different in COPD 
participants with and without emphysema whilst PV1 measurements were significantly 
different between COPD participants with emphysema and ex-smokers, both findings in 
agreement with the concept that emphysema, ventilation and the pulmonary vasculature 
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are necessarily and mechanistically linked in COPD patients to avoid ventilation-perfusion 
mismatch.24,38-41 
Third, we stratified participants based on the annual rate of change in FEV1, similar to what 
was previously described in the ECLIPSE study.13 While the annual rate of change in FEV1 
(-40 ±93mL/year) was not different among participant subgroups, the annual rate of change 
in RA950 and PV1 was significantly different in participants with an accelerated annual rate 
of FEV1 decline as compared to participants with a diminished annual rate of FEV1 decline. 
Previous work also reported diminished small vessel volume in COPD patients over 
time21,38,42,43 while others reported a significant increase in small vessel volume in ex-
smokers over a similar follow-up time.19 Possible ways to explain these divergent results 
include a role for angiogenesis in chronic inflammation and tissue repair and remodeling 
of both the pulmonary and bronchial vasculature,44-47 previously validated in COPD 
patients.24,47 Similar findings were not observed for the annual rate of change in VDP, 
indicative that changes in small airway function measured using VDP17 poorly reflect 
changes in FEV1, which is dominated by large airway function. In contrast, there was a 
significantly different rate of change in RA950 in participants in whom FEV1 improved by 
more than 20mL/year as compared to the subgroup in whom FEV1 decreased by more than 
40mL. Moreover, the subgroup reporting the largest annual rate of FEV1 decline was 
dominated by GOLD II participants (10/23 or 44%) which is important because the GOLD 
II subgroup was the only one to report significant worsening of emphysema.  
Finally, we also observed that PV1 weakly correlated with baseline FEV1 %pred, FEV1/FVC 
and RA950, but not DLCO or VDP. The mean PV1 change was significantly related to the 
change in RA950 and the relationship for rate of change in both measurements was also 
significant.  These findings are consistent with what has been previously reported, where 
pulmonary function and small vessel volume are related, but not consistently, in COPD 
patients.48 Small vessel volume and emphysema were previously shown to be related in 
patients with COPD,20 although worsening emphysema and pulmonary vessel volume were 
not related in a linear fashion over time.19 Previous work investigating the relationship 
between ventilation and perfusion also reported their modest relationship which appeared 
to be independent of disease severity.40 Given the potential relevance of these study 
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findings for the clinical management of COPD patients, we think it is time for the field to 
consider ways to implement ventilation MRI and especially CT in clinical workflows and 
this is especially the case for automated image analysis and data reporting, research that 
our group and others are currently undertaking. 
We acknowledge a number of study limitations including the relatively small sample size 
compared to other cohort studies that included imaging measurements such as 
CanCOLD,12 ECLIPSE,9,13 and COPDGene,9,13 although to our knowledge, no other 
COPD cohort study has evaluated lung volume matched MRI and CT datasets to probe 
ventilation and pulmonary vascular changes over time.  In addition, as compared to other 
recent studies,20,21,42 our CT measurement approach may underestimate the fraction of 
small pulmonary vessels in our results. It is important to note that the TINCan study was 
required to compromise between the acquisition of volume matched MRI and CT (at 
FRC+1L) versus full inspiration MRI and CT, mainly due to the costs of 3He gas and 
because the standard in the field was to acquire MRI at FRC+1L. However, as compared 
to plethysmographic measurements of TLC, for the participants studied here, FRC+1L 
values were within 80% to 90% of plethysmographic TLC, which is similar to other CT 
studies for inhalation breath-holds in supine participants or patients.  Moreover, Madani 
and colleagues49 also previously reported that such differences related to lung volume are 
within a few percent for RA950 values and that these are unlikely to be clinically relevant. 
 Conclusions 
We evaluated 90 ex-smokers with and without COPD over 2.5 years and observed that the 
annual RA950 and PV1 rates of change were greater in participants with an accelerated FEV1 
decline. The annual changes in PV1 were weakly related to the annual change in RA950 but 
not VDP. Taken together, these findings suggest that changes over time in the pulmonary 
vessels and ventilation may be asynchronous in ex-smokers and COPD patients.  
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 Supplemental Data 
Table 2.3:  Imaging data at baseline by COPD subgroup  
P-values reflect a one-way ANOVA testing for subgroup differences with Tukey’s post-
hoc correction for multiple comparisons. An independent t-test was used to determine 
differences between ES and C subgroups where * reflects significantly different than ES,  
reflects significantly different than GI, and ⁋ reflects significantly different than GII. 
ES=ex-smokers; C=all COPD; G=GOLD; I=mild; II=moderate; III/IV=severe; 
RA950=relative area of lung with CT attenuation <-950 HU; VDP=ventilation defect 
percent; TBV=CT total blood volume; PV1=relative volume of pulmonary vessels with 
radius <1 voxel. 
  
Parameter (±SD) 
ES 
n=41 
C 
n=49 
GI 
n=15 
GII 
n=23 
GIII/IV 
n=11 
p-value 
RA950 1 (1) 9 (9)* 4 (3) 10 (10)*# 15 (11)*# .0001 
VDP 7 (4) 17 (10)* 8 (4) 17 (9)*# 29 (5)*#! .0001 
TBV 116 (24)* 149 (31)* 134 (29)* 145 (27)* 167 (25)*# .0001 
PV1 49 (4) 52 (6)* 51 (5) 52 (6)*# 53 (6)*# .01 
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Table 2.4:  Baseline and rate of change imaging measurements in subgroups 
dichotomized by CT emphysema 
 
Participants with COPD were dichotomized based on the presence of CT emphysema using 
the validated CT RA950 threshold ( 6.8%). P-values reflect results of a one-way ANOVA 
for significant differences between subgroups with Tukey’s post-hoc correction for 
multiple comparisons. An independent t-test was used to determine differences between 
subgroups whereby: * reflects significantly different than all ex-smokers, and  reflects 
significantly different than COPD with no CT emphysema; ND=not done; TBV=CT total 
blood volume; VDP=ventilation defect percent; PV1=relative volume of pulmonary vessels 
with radius <1 voxel; RA950=relative area of lung CT attenuation <-950 HU.  
  
Parameter (±SD) 
 
All  
Ex-smokers 
n=41 
 
COPD  
No CT emphysema 
n=26 
 
COPD  
CT Emphysema 
n=23 
p-value 
RA950 % 1 (1) 3 (2) 17 (9)*# ND 
VDP % 7 (4) 11 (8)* 22 (9)*# .0001 
TBV mL 116 (24) 140 (31)* 159 (30)* .0001 
PV1 % 49 (4) 51 (5) 53 (6)* .003 
DRA950 %/yr 1 (2) 0 (1) 0 (6) .878 
DVDP %/yr 1 (2) 1 (2) 2 (4) .113 
DTBV %/yr 1 (9) -4 (10) -3 (6) .061 
DPV1 %/yr 0 (2) -1 (2)* 0 (1) .013 
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Table 2.5:  Demographics for participants who attended both baseline and follow-
up: Unpaired analysis to account for changes in subgroup participants over time 
 
BL=baseline, FU=Follow-up, BMI=body mass index, SaO2=oxygen saturation, 
6MWD=six minute walk distance, %pred=percent predicted, FEV1=forced expiratory 
volume in 1 second, FVC=forced vital capacity, RV=residual volume, TLC=total lung 
capacity, DLCO=diffusing capacity of the lung to carbon monoxide. Unpaired Student’s t-
tests were used to test for group changes at follow-up. 
  
 Ex-smoker GOLD I GOLD II GOLD III/IV 
Parameter 
(±SD) 
BL 
n=41 
FU 
n=40 
p-
value 
BL 
n=15 
FU 
n=15 
p-
value 
BL 
n=23 
FU 
n=21 
p-
value 
BL 
n=11 
FU 
n=14 
p-
value 
Female n (%) 18 (44) 17 (43) - 1 (7) 1 (7) - 11 (48) 11 (52) - 4 (36) 2 (14) - 
Age y  71 (10) 73 (10) .325 75 (8) 80 (8) .243 68 (7) 72 (7) .126 66 (16) 72 (11) .310 
BMI kg/m2 30 (4) 30 (4) .813 28 (4) 27 (4) .630 26 (4) 27 (4) .411 26 (6) 25 (5) .572 
SaO2 % 95 (5) 96 (2) .782 96 (1) 95 (3) .088 96 (2) 95 (3) .092 95 (2) 94 (3) .419 
6MWD m 417 (83) 409 (74) .593 434 (39) 397 (87) .176 423 (71) 401 (57) .463 358 (81) 363 (110) .909 
FEV1 %pred 102 (18) 103 (20) .640 97 (12) 102 (13) .556 62 (8) 63 (10) .642 40 (5) 38 (7) .380 
FVC %pred 94 (17) 96 (18) .521 111 (13) 117 (12) .235 94 (13) 88 (11) .132 75 (10) 72 (17) .616 
FEV1/FVC 81 (6) 80 (6) .414 64 (4) 62 (5) .260 50 (9) 54 (9) .219 41 (7) 40 (8) .898 
RV %pred 105 (20) 101 (20) .250 116 (27) 128 (32) .141 140 (25) 136 (26) .665 203 (44) 184 (46) .312 
TLC %pred 101 (11) 96 (12) .028 111 (11) 115 (18) .252 113 (14) 108 (14) .267 123 (21) 118 (17) .506 
RV/TLC %pred 103 (15) 104 (16) .800 104 (18) 110 (15) .180 123 (17) 125 (14) .701 162 (18) 152 (23) .263 
DLCO %pred 79 (16) 85 (17) .037 76 (20) 78 (21) .654 60 (16) 62 (22) .436 45 (13) 46 (13) .897 
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CHAPTER 3 
3 CONCLUSIONS AND FUTURE DIRECTIONS 
In the previous chapter, main hypotheses and objectives of this thesis were addressed. In 
this section, the main findings of this work are summarized, and study limitations and 
future directions are explored. This section also contains a summary of the impact and 
significance of this work on the field and broader scientific community. 
 Overview and Research Questions 
The purpose of this work is to explore the relationships between imaging and clinical 
biomarkers of chronic obstructive pulmonary disease, and specifically the role of CT 
measurements of vascular remodeling in informing disease stage and progression. The goal 
of this thesis was to address a gap in the literature by investigating the relationships 
between CT blood vessel volume measurements with hyperpolarized gas MR imaging in 
COPD. Additionally, we sought to determine whether small blood vessel volume 
measurements might serve as an informative structural biomarker that serves to indicate 
disease progression alongside established functional measurement methods. 
 Summary and Conclusions 
In Chapter 1, we discussed the motivation and rationale for the study of COPD and the 
gaps in clinical knowledge that this work intends to inform. We also discussed the structure 
and function of the lungs, and the pathophysiological changes that occur respectively in 
the context of disease. We then reviewed clinical measures of lung function including 
pulmonary function testing, symptom reporting and exercise testing, as well as both 
structural and functional imaging methods. To conclude the chapter, we outlined the thesis 
hypotheses and objectives, which were: 
1) To compare CT blood vessel volume measurements in ex-smokers without COPD 
and those with mild, moderate, and severe disease, and  
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2) To evaluate relationships between imaging and clinical biomarkers of chronic 
obstructive pulmonary disease, and 
3)  To investigate disease progression in COPD using multimodality imaging.  
We hypothesized that CT blood vessel volume measurements were significantly different 
in ex-smokers without COPD than in those with this disease and will be related to disease 
severity. In Chapter 2, we addressed these aims: 
 
1) In a cross-sectional sample of ex-smokers without COPD and participants with mild, 
moderate and severe disease, we confirmed our hypothesis and demonstrated that small 
blood vessel volume is significantly different in COPD than in ex-smokers without COPD 
and is related to disease severity. In this study we demonstrated that in 90 ex-smokers with 
and without COPD over a follow-up period of 2.5 years, there were significant differences 
between ex-smokers and mild, moderate and severe COPD for imaging measurements of 
CT RA950, TBV, PV1 and MRI VDP.   
  
2) In this study, we also demonstrated that the rates of change in imaging measurements 
from baseline to follow-up were significantly different according to the rate of change in 
FEV1; RA950 and PV1 demonstrated changes between groups, whereas VDP was the same 
across each group, demonstrating that changes in small vessel volume and emphysema on 
CT are sensitive to changes in lung function that VDP is not.  
 
3) Finally, changes in PV1 according to the presence of emphysema in whereas other 
imaging measurements did not significantly differentiate groups according to phenotype. 
This indicates that disease progression occurs differently according to COPD phenotype.  
 
We concluded that small blood vessel volume may be an important indicatory of disease 
progression, and that combining CT and MRI measurements of lung structure and function, 
respectively, can inform a deeper understanding of COPD progression.  
  
 
66 
 Limitations 
A limitation of this work is the consequence of non-isotropic CT voxel size on peripheral 
vascular structure measurements. Based on the algorithm that was used by VIDA Vision 
commercial software, peripheral vessels are defined as a vessel with a radius of less than 
one voxel. Because of the non-isotropic voxel size used in our acquisition protocol, it is 
unclear in which plane the radius is being measured, which would affect the threshold 
diameter of peripheral vessels. Despite this limitation, even if a radius of 1.25mm is used 
as a threshold, this would mean a cross sectional area of approximately 5mm2, which is 
consistent with methods reported in other studies.1-3 Other specific limitations were 
discussed in Chapter 2. 
 
 Future Directions 
In the future, it would be interesting to spatially match hyperpolarized gas MRI and CT 
vascular structure in bronchiectasis, as a model of airway remodeling. In approximately 
50% of COPD cases, patients experience an irreversible cycle of marked airway 
inflammation, infection, obstruction, and damage.4 The current gold-standard for the 
diagnosis of bronchiectasis is CT, wherein the radiologist looks for the signet ring sign, a 
mismatched ratio between the cross-sectional diameter of the airway and its associated 
vessel. Another radiological marker of bronchiectasis is the traction sign, or airways that 
do not appear to taper as they travel distal from the main airways.5 There is no way to 
reverse this disease. The consequences for the patient are symptoms such as chronic cough, 
repeated chest infection, shortness of breath and decreased pulmonary function. In patients 
with COPD, the presence of bronchiectasis results in decreased quality of life, increased 
rates of hospitalization and disease exacerbation, and increased morbidity and mortality.4,6  
Further, the consideration of clinical COPD phenotypes in evaluating vascular changes 
within the lung should be considered. Studies in healthy never smokers and in ex-smokers 
without COPD have reported some emphysema on CT scans, however the upper limit of 
normal has been reported as 6.8%.7 Differences in vascular measurements between the 
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chronic bronchitis predominant compared to emphysema predominant case may be 
reflective of different underlying physiological processes, as discussed in sections 1.3.1 to 
1.3.3. 
Another important future direction for this work is to investigate the of the role of sex 
differences in airways disease, as this factor is becoming an important consideration for 
COPD diagnosis and management.8 Interestingly, bronchiectasis differentially affects men 
and women differently throughout their lifespan. In childhood, boys are more likely to be 
diagnosed with non-cystic fibrosis bronchiectasis. Later in adulthood, this trend is reversed, 
wherein women over the age of 60 are twice as likely to be diagnosed.9 This likely 
represents a complex interplay between genetic, hormonal and environmental factors 
related to the disease.8 Further, men and women experience chronic lung disease such as 
COPD differently; women are more likely to report greater symptom severity and to 
experience psychological effects of chronic disease than men.8 An interesting future study 
would investigate sex differences in disease progression and vascular remodeling in 
consideration of disease severity and burden. 
Finally, another potential future direction for this work given the results of this study would 
be the application of machine learning to predict disease progression using CT vessel 
measurements and MRI. This method has been used to predict MRI ventilation from CT 
images,10 as well as to predict disease progression in COPD using baseline and follow-up 
data according to disease phenotypes.11 Application of machine learning in this case would 
include identifying participants at risk of disease progression based on vascular structure. 
The ground truth for this method would be based on patients who experienced an increase 
in ventilation defect percent or decline in lung function according to clinical PFT data. 
Input data would include maps of vascular structure, emphysema, and MR ventilation 
maps. Not only would this method be important for determining which participants are at 
risk of disease progression but could also elucidate relationships about 
ventilation/perfusion mismatch and what that means for COPD prognosis. Recently, 
researchers involved in the COPDGene study have proposed that perhaps COPD 
phenotypes may not exist, but rather a series of axes related to inflammation, disease 
trajectory, and genetic factors.12 Further, they highlight the importance of chest CT in our 
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developing understanding of this disease. It is therefore important to continue to investigate 
the diagnostic and predictive role of imaging biomarkers to further elucidate factors related 
to disease morbidity and mortality. 
 Significance and Impact 
This work contributes significantly to the literature as a novel study comparing CT vascular 
structure and MRI ventilation in COPD, and what this tells us about disease progression 
and functional changes. While changes to MRI ventilation did not correlate significantly 
with changes to vascular structure, it is likely that one change precedes the other, and 
depends on disease presentation. To our knowledge, this is the first study to compare 
clinically important biomarkers using multimodality imaging of both lung CT structure and 
MRI lung function in COPD.  This work has a significant impact due to the importance of 
understanding ventilation-perfusion relationships in COPD, as well as supporting 
peripheral vascular structure as an important measurement in COPD progression. In the 
bigger picture, this work also supports the application of multimodality imaging which 
provides important structural and functional measurements.  
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matter other than works listed in Section 1(g) below, which, by reason of the selection 
and arrangement of their contents, constitute intellectual creations, in which the Work is 
included in its entirety in unmodified form along with one or more other contributions, 
each constituting separate and independent works in themselves, which together are 
assembled into a collective whole. A work that constitutes a Collection will not be 
considered an Adaptation (as defined above) for the purposes of this License. 
c. "Distribute" means to make available to the public the original and copies of the Work or 
Adaptation, as appropriate, through sale or other transfer of ownership. 
d. "License Elements" means the following high-level license attributes as selected by 
Licensor and indicated in the title of this License: Attribution, Noncommercial, ShareAlike. 
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e. "Licensor" means the individual, individuals, entity or entities that offer(s) the Work 
under the terms of this License. 
f. "Original Author" means, in the case of a literary or artistic work, the individual, 
individuals, entity or entities who created the Work or if no individual or entity can be 
identified, the publisher; and in addition (i) in the case of a performance the actors, 
singers, musicians, dancers, and other persons who act, sing, deliver, declaim, play in, 
interpret or otherwise perform literary or artistic works or expressions of folklore; (ii) in the 
case of a phonogram the producer being the person or legal entity who first fixes the 
sounds of a performance or other sounds; and, (iii) in the case of broadcasts, the 
organization that transmits the broadcast. 
g. "Work" means the literary and/or artistic work offered under the terms of this License 
including without limitation any production in the literary, scientific and artistic domain, 
whatever may be the mode or form of its expression including digital form, such as a 
book, pamphlet and other writing; a lecture, address, sermon or other work of the same 
nature; a dramatic or dramatico-musical work; a choreographic work or entertainment in 
dumb show; a musical composition with or without words; a cinematographic work to 
which are assimilated works expressed by a process analogous to cinematography; a 
work of drawing, painting, architecture, sculpture, engraving or lithography; a 
photographic work to which are assimilated works expressed by a process analogous to 
photography; a work of applied art; an illustration, map, plan, sketch or three-dimensional 
work relative to geography, topography, architecture or science; a performance; a 
broadcast; a phonogram; a compilation of data to the extent it is protected as a 
copyrightable work; or a work performed by a variety or circus performer to the extent it is 
not otherwise considered a literary or artistic work. 
h. "You" means an individual or entity exercising rights under this License who has not 
previously violated the terms of this License with respect to the Work, or who has 
received express permission from the Licensor to exercise rights under this License 
despite a previous violation. 
i. "Publicly Perform" means to perform public recitations of the Work and to communicate 
to the public those public recitations, by any means or process, including by wire or 
wireless means or public digital performances; to make available to the public Works in 
such a way that members of the public may access these Works from a place and at a 
place individually chosen by them; to perform the Work to the public by any means or 
process and the communication to the public of the performances of the Work, including 
by public digital performance; to broadcast and rebroadcast the Work by any means 
including signs, sounds or images. 
j. "Reproduce" means to make copies of the Work by any means including without 
limitation by sound or visual recordings and the right of fixation and reproducing fixations 
of the Work, including storage of a protected performance or phonogram in digital form or 
other electronic medium. 
2. Fair Dealing Rights. Nothing in this License is intended to reduce, limit, or restrict any uses free 
from copyright or rights arising from limitations or exceptions that are provided for in connection 
with the copyright protection under copyright law or other applicable laws. 
3. License Grant. Subject to the terms and conditions of this License, Licensor hereby grants You 
a worldwide, royalty-free, non-exclusive, perpetual (for the duration of the applicable copyright) 
license to exercise the rights in the Work as stated below: 
  
 
76 
a. to Reproduce the Work, to incorporate the Work into one or more Collections, and to 
Reproduce the Work as incorporated in the Collections; 
b. to create and Reproduce Adaptations provided that any such Adaptation, including any 
translation in any medium, takes reasonable steps to clearly label, demarcate or 
otherwise identify that changes were made to the original Work. For example, a 
translation could be marked "The original work was translated from English to Spanish," 
or a modification could indicate "The original work has been modified."; 
c. to Distribute and Publicly Perform the Work including as incorporated in Collections; and, 
d. to Distribute and Publicly Perform Adaptations. 
The above rights may be exercised in all media and formats whether now known or hereafter 
devised. The above rights include the right to make such modifications as are technically necessary 
to exercise the rights in other media and formats. Subject to Section 8(f), all rights not expressly 
granted by Licensor are hereby reserved, including but not limited to the rights described in Section 
4(e). 
4. Restrictions. The license granted in Section 3 above is expressly made subject to and limited 
by the following restrictions: 
a. You may Distribute or Publicly Perform the Work only under the terms of this License. 
You must include a copy of, or the Uniform Resource Identifier (URI) for, this License with 
every copy of the Work You Distribute or Publicly Perform. You may not offer or impose 
any terms on the Work that restrict the terms of this License or the ability of the recipient 
of the Work to exercise the rights granted to that recipient under the terms of the License. 
You may not sublicense the Work. You must keep intact all notices that refer to this 
License and to the disclaimer of warranties with every copy of the Work You Distribute or 
Publicly Perform. When You Distribute or Publicly Perform the Work, You may not 
impose any effective technological measures on the Work that restrict the ability of a 
recipient of the Work from You to exercise the rights granted to that recipient under the 
terms of the License. This Section 4(a) applies to the Work as incorporated in a 
Collection, but this does not require the Collection apart from the Work itself to be made 
subject to the terms of this License. If You create a Collection, upon notice from any 
Licensor You must, to the extent practicable, remove from the Collection any credit as 
required by Section 4(d), as requested. If You create an Adaptation, upon notice from any 
Licensor You must, to the extent practicable, remove from the Adaptation any credit as 
required by Section 4(d), as requested. 
b. You may Distribute or Publicly Perform an Adaptation only under: (i) the terms of this 
License; (ii) a later version of this License with the same License Elements as this 
License; (iii) a Creative Commons jurisdiction license (either this or a later license 
version) that contains the same License Elements as this License (e.g., Attribution-
NonCommercial-ShareAlike 3.0 US) ("Applicable License"). You must include a copy of, 
or the URI, for Applicable License with every copy of each Adaptation You Distribute or 
Publicly Perform. You may not offer or impose any terms on the Adaptation that restrict 
the terms of the Applicable License or the ability of the recipient of the Adaptation to 
exercise the rights granted to that recipient under the terms of the Applicable License. 
You must keep intact all notices that refer to the Applicable License and to the disclaimer 
of warranties with every copy of the Work as included in the Adaptation You Distribute or 
Publicly Perform. When You Distribute or Publicly Perform the Adaptation, You may not 
impose any effective technological measures on the Adaptation that restrict the ability of 
a recipient of the Adaptation from You to exercise the rights granted to that recipient 
  
 
77 
under the terms of the Applicable License. This Section 4(b) applies to the Adaptation as 
incorporated in a Collection, but this does not require the Collection apart from the 
Adaptation itself to be made subject to the terms of the Applicable License. 
c. You may not exercise any of the rights granted to You in Section 3 above in any manner 
that is primarily intended for or directed toward commercial advantage or private 
monetary compensation. The exchange of the Work for other copyrighted works by 
means of digital file-sharing or otherwise shall not be considered to be intended for or 
directed toward commercial advantage or private monetary compensation, provided there 
is no payment of any monetary compensation in con-nection with the exchange of 
copyrighted works. 
d. If You Distribute, or Publicly Perform the Work or any Adaptations or Collections, You 
must, unless a request has been made pursuant to Section 4(a), keep intact all copyright 
notices for the Work and provide, reasonable to the medium or means You are utilizing: 
(i) the name of the Original Author (or pseudonym, if applicable) if supplied, and/or if the 
Original Author and/or Licensor designate another party or parties (e.g., a sponsor 
institute, publishing entity, journal) for attribution ("Attribution Parties") in Licensor's 
copyright notice, terms of service or by other reasonable means, the name of such party 
or parties; (ii) the title of the Work if supplied; (iii) to the extent reasonably practicable, the 
URI, if any, that Licensor specifies to be associated with the Work, unless such URI does 
not refer to the copyright notice or licensing information for the Work; and, (iv) consistent 
with Section 3(b), in the case of an Adaptation, a credit identifying the use of the Work in 
the Adaptation (e.g., "French translation of the Work by Original Author," or "Screenplay 
based on original Work by Original Author"). The credit required by this Section 4(d) may 
be implemented in any reasonable manner; provided, however, that in the case of a 
Adaptation or Collection, at a minimum such credit will appear, if a credit for all 
contributing authors of the Adaptation or Collection appears, then as part of these credits 
and in a manner at least as prominent as the credits for the other contributing authors. 
For the avoidance of doubt, You may only use the credit required by this Section for the 
purpose of attribution in the manner set out above and, by exercising Your rights under 
this License, You may not implicitly or explicitly assert or imply any connection with, 
sponsorship or endorsement by the Original Author, Licensor and/or Attribution Parties, 
as appropriate, of You or Your use of the Work, without the separate, express prior 
written permission of the Original Author, Licensor and/or Attribution Parties. 
e. For the avoidance of doubt: 
i. Non-waivable Compulsory License Schemes. In those jurisdictions in which 
the right to collect royalties through any statutory or compulsory licensing 
scheme cannot be waived, the Licensor reserves the exclusive right to collect 
such royalties for any exercise by You of the rights granted under this License; 
ii. Waivable Compulsory License Schemes. In those jurisdictions in which the 
right to collect royalties through any statutory or compulsory licensing scheme 
can be waived, the Licensor reserves the exclusive right to collect such royalties 
for any exercise by You of the rights granted under this License if Your exercise 
of such rights is for a purpose or use which is otherwise than noncommercial as 
permitted under Section 4(c) and otherwise waives the right to collect royalties 
through any statutory or compulsory licensing scheme; and, 
iii. Voluntary License Schemes. The Licensor reserves the right to collect 
royalties, whether individually or, in the event that the Licensor is a member of a 
collecting society that administers voluntary licensing schemes, via that society, 
from any exercise by You of the rights granted under this License that is for a 
purpose or use which is otherwise than noncommercial as permitted under 
Section 4(c). 
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f. Except as otherwise agreed in writing by the Licensor or as may be otherwise permitted 
by applicable law, if You Reproduce, Distribute or Publicly Perform the Work either by 
itself or as part of any Adaptations or Collections, You must not distort, mutilate, modify 
or take other derogatory action in relation to the Work which would be prejudicial to the 
Original Author's honor or reputation. Licensor agrees that in those jurisdictions (e.g. 
Japan), in which any exercise of the right granted in Section 3(b) of this License (the right 
to make Adaptations) would be deemed to be a distortion, mutilation, modification or 
other derogatory action prejudicial to the Original Author's honor and reputation, the 
Licensor will waive or not assert, as appropriate, this Section, to the fullest extent 
permitted by the applicable national law, to enable You to reasonably exercise Your right 
under Section 3(b) of this License (right to make Adaptations) but not otherwise. 
5. Representations, Warranties and Disclaimer 
UNLESS OTHERWISE MUTUALLY AGREED TO BY THE PARTIES IN WRITING AND TO THE 
FULLEST EXTENT PERMITTED BY APPLICABLE LAW, LICENSOR OFFERS THE WORK AS-
IS AND MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE 
WORK, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, INCLUDING, WITHOUT 
LIMITATION, WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR 
PURPOSE, NONINFRINGEMENT, OR THE ABSENCE OF LATENT OR OTHER DEFECTS, 
ACCURACY, OR THE PRESENCE OF ABSENCE OF ERRORS, WHETHER OR NOT 
DISCOVERABLE. SOME JURISDICTIONS DO NOT ALLOW THE EXCLUSION OF IMPLIED 
WARRANTIES, SO THIS EXCLUSION MAY NOT APPLY TO YOU. 
6. Limitation on Liability. EXCEPT TO THE EXTENT REQUIRED BY APPLICABLE LAW, IN NO 
EVENT WILL LICENSOR BE LIABLE TO YOU ON ANY LEGAL THEORY FOR ANY SPECIAL, 
INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR EXEMPLARY DAMAGES ARISING OUT OF 
THIS LICENSE OR THE USE OF THE WORK, EVEN IF LICENSOR HAS BEEN ADVISED OF 
THE POSSIBILITY OF SUCH DAMAGES. 
7. Termination 
a. This License and the rights granted hereunder will terminate automatically upon any 
breach by You of the terms of this License. Individuals or entities who have received 
Adaptations or Collections from You under this License, however, will not have their 
licenses terminated provided such individuals or entities remain in full compliance with 
those licenses. Sections 1, 2, 5, 6, 7, and 8 will survive any termination of this License. 
b. Subject to the above terms and conditions, the license granted here is perpetual (for the 
duration of the applicable copyright in the Work). Notwithstanding the above, Licensor 
reserves the right to release the Work under different license terms or to stop distributing 
the Work at any time; provided, however that any such election will not serve to withdraw 
this License (or any other license that has been, or is required to be, granted under the 
terms of this License), and this License will continue in full force and effect unless 
terminated as stated above. 
8. Miscellaneous 
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a. Each time You Distribute or Publicly Perform the Work or a Collection, the Licensor offers 
to the recipient a license to the Work on the same terms and conditions as the license 
granted to You under this License. 
b. Each time You Distribute or Publicly Perform an Adaptation, Licensor offers to the 
recipient a license to the original Work on the same terms and conditions as the license 
granted to You under this License. 
c. If any provision of this License is invalid or unenforceable under applicable law, it shall 
not affect the validity or enforceability of the remainder of the terms of this License, and 
without further action by the parties to this agreement, such provision shall be reformed 
to the minimum extent necessary to make such provision valid and enforceable. 
d. No term or provision of this License shall be deemed waived and no breach consented to 
unless such waiver or consent shall be in writing and signed by the party to be charged 
with such waiver or consent. 
e. This License constitutes the entire agreement between the parties with respect to the 
Work licensed here. There are no understandings, agreements or representations with 
respect to the Work not specified here. Licensor shall not be bound by any additional 
provisions that may appear in any communication from You. This License may not be 
modified without the mutual written agreement of the Licensor and You. 
f. The rights granted under, and the subject matter referenced, in this License were drafted 
utilizing the terminology of the Berne Convention for the Protection of Literary and Artistic 
Works (as amended on September 28, 1979), the Rome Convention of 1961, the WIPO 
Copyright Treaty of 1996, the WIPO Performances and Phonograms Treaty of 1996 and 
the Universal Copyright Convention (as revised on July 24, 1971). These rights and 
subject matter take effect in the relevant jurisdiction in which the License terms are 
sought to be enforced according to the corresponding provisions of the implementation of 
those treaty provisions in the applicable national law. If the standard suite of rights 
granted under applicable copyright law includes additional rights not granted under this 
License, such additional rights are deemed to be included in the License; this License is 
not intended to restrict the license of any rights under applicable law. 
https://creativecommons.org/licenses/by-nc-sa/3.0/legalcode 
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